

chain nodes :

21 22 24 25 26 27 28 29 30 31 32 33 34 35 38 39 40 43
51

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 23

chain bonds :

8-21 8-22 15-24 15-25 26-27 26-35 27-28 28-29 29-30 30-31 31-32
32-33 32-34 35-38 38-39 39-40 40-43 40-51

ring bonds :

1-2 1-6 1-19 2-3 3-4 4-5 4-19 5-6 7-8 7-12 7-20 8-9 9-10
9-20 10-11 11-12 13-14 13-18 14-15 14-23 15-16 16-17 16-23
17-18

exact/norm bonds :

1-2 1-6 1-19 2-3 3-4 4-5 4-19 5-6 7-8 7-12 7-20 8-9 9-10
9-20 10-11 11-12 13-14 13-18 14-15 14-23 15-16 16-17 16-23
17-18 26-35 32-33 32-34 35-38 38-39 39-40 40-43 40-51

exact bonds :

8-21 8-22 15-24 15-25 26-27 27-28 28-29 29-30 30-31 31-32

G1:[*1-*2],[*3-*4],[*5-*6]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom
18:Atom 19:Atom 20:Atom 21:CLASS 22:CLASS 23:Atom 24:CLASS
25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 38:CLASS 39:CLASS 40:CLASS
43:CLASS

51:Atom

09/936,161

=> d his

(FILE 'HOME' ENTERED AT 14:54:02 ON 31 JAN 2003)

FILE 'REGISTRY' ENTERED AT 14:54:08 ON 31 JAN 2003

L1 STRUCTURE UPLOADED
L2 QUE L1
L3 49 S L2
L4 STRUCTURE UPLOADED
L5 QUE L4
L6 40 S L5
L7 836 S L5 SSS FUL

FILE 'CAPLUS' ENTERED AT 14:58:10 ON 31 JAN 2003

L8 17 S L7

=> d 15

L5 HAS NO ANSWERS

L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L5 QUE ABB=ON PLU=ON L4

=> d 18 bib abs hitstr 1-17

09/936,161

ANSWER 1 OF 17 CAPLUS COPYRIGHT 2003 ACS

AN 2002:314933 CAPLUS

DN 136:327386

TI Process for the preparation of PGD2 antagonist

IN Larsen, Robert; Cai, Dongwei; Journet, Michel; Campos, Kevin

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 19 pp.

CODEN: PIKX02


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002032892	A1	20020425	WO 2001-US42763	20011016
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002013505	A5	20020429	AU 2002-13505	20011016
PRAI US 2000-241027P	P	20001017		
WO 2001-US42763	W	20011016		
AB	Present invention provides an efficient process for the prepn. of benzothienophenecarboxamide PGD2 antagonist, 5-5751.			
IT 209268-36-0P				
RL:	IMF (Industrial manufacture); PREP (Preparation) (process for prepn. of pgd2 antagonist)			
RN 209268-36-0 CAPLUS				
CN	5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-2-[[[(5-hydroxybenzo(b)thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)			

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS

AN 2001:904102 CAPLUS

DN 136:37614

TI Preparation of chiral heterocyclylcarbonylaminobicycloheptanehydrocarboncarboxylic acids in remedy composition antagonistic to both PGD2 and TXA2 receptors

IN Tanimoto, Norihiko; Arimura, Akinori

PA Shionogi & Co., Ltd., Japan

SO PCT Int. Appl., 278 pp.



CODEN: PIKX02

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001094309	A1	20011213	WO 2001-JP4430	20010528
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI JP 2000-166305	A	20000602		
OS MARPAT 136:37614				
GI				



AB Title compds. [I: A = alkylene optionally having an unsatd. bond; R = COR1, CH2OCH3, CH2OH; R1 = OH, OCH3, NH2, NHSO2CH3; X1, X3 independently = optionally substituted aryl, optionally substituted heteroaryl; X2 = single bond, CH2, S, SO2, CH2O, OCH2, CH2S, SCH2; Y = bicycloheptane] and

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
pharmaceutically acceptable salts or solvates, having antagonistic effect on both thromboxane A2 and prostaglandin D2 receptors, are prepd. Thus, the title compd. II was prepd. and biol. tested for TXA2 receptor antagonistic activity with IC50(.mu.M) = 0.011 and PGD2 receptor antagonistic activity with IC50(.mu.M) = 0.079.

IT 186532-85-4P 186532-96-7P 217772-88-4P

217772-90-8P 217772-92-0P 217772-94-2P

217772-95-3P 217772-96-4P 217772-97-5P

217772-98-6P 217772-99-7P 217773-00-3P

217773-01-4P 217773-02-5P 217773-03-6P

217773-04-7P 217773-05-8P 217773-06-9P

217773-07-0P 217773-08-1P 217773-09-2P

217773-10-3P 217773-11-4P 217773-12-5P

217773-13-6P 217773-14-7P 217773-15-8P

217773-16-9P 217773-17-0P 217773-18-3P

217773-19-4P 217773-20-7P 217773-21-8P

217773-22-9P 217773-23-0P 217773-24-1P

217773-25-2P 217773-26-3P 217773-27-4P

217773-28-5P 217773-29-6P 217773-30-9P

217773-31-0P 217773-32-1P 217773-33-2P

217773-34-3P 217773-35-4P 217773-36-5P

217773-37-6P 217773-38-7P 217773-39-8P

217773-40-9P 217773-41-0P 217773-42-3P

217773-43-4P 217773-44-5P 217773-45-6P

217773-46-7P 217773-47-8P 217773-48-9P

217773-49-0P 217773-50-3P 217773-51-4P

217773-52-5P 217773-53-6P 217773-54-7P

217773-55-8P 217773-56-9P 217773-57-0P

217773-58-1P 217773-59-2P 217773-60-3P

217773-61-4P 217773-62-5P 217773-63-6P

217773-64-7P 217773-65-8P 217773-66-9P

217773-67-0P 217773-68-3P 217773-69-4P

217773-70-5P 217773-71-8P 217773-72-9P

217773-73-0P 217773-74-1P 217773-75-2P

217773-76-3P 217773-77-4P 217773-78-5P

217773-79-6P 217773-80-9P 217773-81-0P

217773-82-1P 217773-83-2P 217773-84-3P

217773-85-4P 217773-86-5P 217773-87-6P

217773-88-7P 217773-89-8P 217773-90-9P

217773-91-0P 217773-92-3P 217773-93-4P

217773-94-5P 217773-95-6P 217773-96-7P

217773-97-8P 217773-98-9P 217774-00-6P

217774-01-7P 217774-02-8P 217774-03-9P

217774-04-0P 217774-05-1P 217774-06-2P

217774-07-3P 217774-08-4P 217774-09-5P

217774-10-6P 217774-11-9P 217774-13-1P

217774-14-2P 217774-15-3P 217774-16-4P

217774-17-5P 217774-18-6P 217774-19-7P

217774-20-8P 217774-21-1P 217774-22-2P

217774-23-3P 217774-25-5P 217774-26-6P

217774-27-7P 217774-28-8P 217774-30-2P

217774-31-3P 217774-32-4P 217774-33-5P

217774-34-6P 217774-35-7P 217774-36-8P

217774-37-9P 217774-38-0P 217774-39-1P

217774-40-2P 217774-41-5P 217774-43-7P

217774-44-8P 217774-45-9P 217774-46-0P

217774-47-1P 217774-48-2P 217774-49-3P

217774-50-4P 217774-52-8P 217774-53-9P

217774-54-0P 217774-55-1P 217774-57-3P

217774-58-4P 217774-59-5P 217774-60-8P

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


217774-61-9P 217774-62-0P 217774-63-1P
217774-64-2P 217774-65-3P 217774-66-4P
217774-67-5P 217774-68-6P 217774-69-7P
217774-70-8P 217774-71-1P 217774-72-2P
217774-73-3P 217774-74-4P 217774-75-5P
217774-76-6P 217774-77-7P 217774-78-8P
217774-80-2P 217774-81-3P 217774-82-4P
217774-83-5P 217774-84-6P 217774-85-7P
217774-86-8P 217774-87-9P 217774-88-0P
217774-89-1P 217774-90-2P 217774-91-3P
217774-92-4P 217774-93-5P 217774-94-6P
217774-95-7P 217774-96-8P 217774-97-9P
217774-98-0P 217774-99-1P 217775-01-2P
217775-02-3P 217775-03-4P 217775-04-5P
217775-05-6P 217775-06-7P 217775-07-8P
217775-08-9P 217775-09-0P 217775-10-3P
217775-11-4P 217775-12-5P 217775-13-6P
217775-14-7P 217775-15-8P

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of chiral heterocyclylcarbonylaminobicycloheptanehydrocarboncarboxylic acids in remedy compn. as PGD2 and TXA2 receptors antagonists)

RN 186532-85-4 CAPLUS

CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-2-[[[(1,3-benzodioxol-5-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 186532-96-7 CAPLUS

CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-2-[[[(1,3-benzodioxol-5-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271772-88-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(3-hydroxyphenyl)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271772-90-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(4-methoxyphenylthio)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271772-92-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[3-(4-methoxyphenylthio)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271772-96-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(phenylsulfonyl)amino]-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271772-97-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(benzoylamino)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271772-98-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(1H-pyrrol-1-ylsulfonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

ino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)
Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271772-94-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(1H-pyrrol-1-yl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271772-95-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(phenylamino)sulfonylbenzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

NAME)
Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271772-99-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(phenylmethyl)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-00-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(phenylsulfonyl)amino]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-01-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-[(phenylamino)sulfonyl]-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-02-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-[(1H-pyrrol-1-ylsulfonyl)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-06-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(2-methyl-1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-07-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(1H-pyrrol-1-ylmethyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271773-03-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(1H-pyrrol-1-ylsulfonyl)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-04-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(3-methyl-1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-05-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(1H-pyrrol-1-ylsulfonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271773-08-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(1H-indol-1-yl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-09-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(2-(hydroxymethyl)-1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-10-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(2-thiazolylamino)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-11-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(2-thiazolylamino)carbonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-12-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-{(1H-pyrrol-1-ylsulfonyl)benzo[b]thien-2-yl}carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271773-15-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(2-pyridinylamino)carbonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-16-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-{(3-thienylthio)benzoyl}amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-17-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-{(3-thienylsulfonyl)benzoyl}amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-13-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-{(2-thienylthio)benzoyl}amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-14-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-{(2-thienylsulfonyl)benzoyl}amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-18-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-{(1H-pyrrol-1-yl)-2-furanyl}carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-19-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-{(phenylmethyl)-2-thienyl}carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-20-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-{(phenylamino)sulfonyl}benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-21-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-ylsulfonyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-23-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-27-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-28-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-phenyl-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-24-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylthio)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-25-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-26-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(benzoylamino)-2-

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-29-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-benzoyl-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-30-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[2,3'-bithiophen]-5-ylcarbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-31-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[2,2'-bithiophen]-5-ylcarbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-33-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(4-methylphenyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-34-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-35-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(4-fluorophenyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-38-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrazol-1-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-39-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(phenylsulfonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-40-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(4-methoxyphenyl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-36-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-37-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-imidazol-1-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-41-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(2-thienylcarbonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-42-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(1H-pyrrol-1-ylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-43-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-yl)-4-(1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-44-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-methyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271773-47-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-methyl-5-(1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-48-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-49-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(phenylthio)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-45-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(benzoylamino)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-46-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-50-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenoxy-2-thienyl)carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-51-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[6-(1H-pyrrol-1-yl)sulfonyl]benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-52-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[2-(benzoylamino)-4-methyl-5-thiazolyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-53-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-methyl-2-(phenylsulfonyl)amino]-5-thiazolyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-54-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[3-methyl-6-phenylimidazo[2,1-b]thiazol-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-57-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-thienylamino)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-58-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(3-thienylamino)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-59-2 CAPLUS

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-55-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(2-thienylmethyl)thio]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-56-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(2-thienylmethyl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(phenylamino)carbonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-60-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[[[4-fluorophenyl]amino]carbonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-61-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[[[4-methoxyphenyl]amino]carbonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 271773-62-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3,4,5-trimethoxyphenyl)amino]carbonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-63-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-yl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-64-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(2-thienylthio)methyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-67-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-(hydroxymethyl)-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-69-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-70-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-65-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(2-thienylthio)methyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-66-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(2-thienylthio)methyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-71-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methyl-2-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-72-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methyl-2-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-73-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methyl-2-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-74-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-(phenylmethyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-75-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-(2-thienylmethyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271773-76-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(4-fluorophenyl)methyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-77-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-(3-thienylmethyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-78-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(3-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-79-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1-(phenylmethyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-80-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1-(2-thienylmethyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-81-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1-(3-thienylmethyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-82-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1-(phenylsulfonyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-83-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-84-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1-(2-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-86-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylthio)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-87-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylthio)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-88-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylthio)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-91-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(5-methyl-3-thienylthio)pent-2-en-1-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-92-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylthio)pent-2-en-1-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-93-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylthio)pent-2-en-1-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-89-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylthio)pent-2-en-1-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-90-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(5-methyl-3-thienylthio)pent-2-en-1-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-94-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylthio)pent-2-en-1-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-95-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylthio)pent-2-en-1-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-96-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylthio)pent-2-en-1-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-97-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylsulfinyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 271773-98-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(5-methyl-2-thienyl)sulfinyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-02-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(methylphenylamino)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-03-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-methylphenyl)thio]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-04-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-methylphenyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271773-99-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylcarbonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-00-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(methoxyimino)-2-thienylmethyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.




RN 271774-01-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylamino)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-05-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-methoxyphenyl)thio]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-06-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-methoxyphenyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-07-3 CAPLUS


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-hydroxyphenyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-08-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-hydroxyphenyl)thio]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-09-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271774-13-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(phenylthio)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-14-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(phenoxymethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-15-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(phenylamino)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-10-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-hydroxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-11-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-(acetyloxy)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271774-16-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-17-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-18-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(phenylsulfonyl)amino]-3-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-19-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[5-(benzoylamino)-3-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-20-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[5-(phenylmethyl)-3-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-25-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[2-phenylbenzo[b]thien-5-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-26-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[3-(1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-27-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[4-(2-methyl-1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271774-21-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[4-(1H-pyrrol-1-yl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-22-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[4-(phenylsulfonyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-23-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[4-(phenylsulfonyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

INDEX NAME)
Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-28-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[4-(1H-pyrrol-1-yl)methyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-30-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[5-(1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271774-31-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(1H-pyrrol-1-ylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-32-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[4-[[2-(hydroxymethyl)-1H-pyrrol-1-yl]sulfonyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271774-33-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(1H-pyrrol-1-ylsulfonyl)-3-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-34-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-thienylsulfonyl)-2-thienylthio]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-35-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[1-(2-thienylsulfonyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-36-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[1-(phenylsulfonyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-37-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-38-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(5-methyl-2-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-39-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(5-methyl-2-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-40-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[1-[(4-fluorophenyl)sulfonyl]-1H-pyrrol-3-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-41-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[1-[(4-methoxyphenyl)sulfonyl]-1H-pyrrol-3-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-43-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(1E)-2-(3-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(5-methyl-3-thienyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-47-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(phenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-48-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(1Z)-2-(2-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-44-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(1Z)-2-(3-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-45-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(5-methyl-3-thienyl)thio]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-46-0 CAPLUS

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271774-49-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(1E)-2-(2-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-50-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-methyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-52-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-thienyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-53-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-methyl-2-thienyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-54-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-55-1 CAPLUS

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-59-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(3-methylphenyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-60-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-methoxyphenyl)thio]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-61-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-methoxyphenyl)sulfonyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-hydroxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-57-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(phenylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-58-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(3-methylphenyl)thio]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-62-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-hydroxyphenyl)sulfonyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-63-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-hydroxyphenyl)thio]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271774-64-2 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 271774-65-3 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(methylphenylamino)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 271774-66-4 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-methylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 271774-70-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1S,2S,3S,5R)-6,6-dimethyl-3-[[[5-(2-thienyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-71-1 CAPLUS


CN 5-Heptenoic acid, 7-[(1S,2S,3S,5R)-6,6-dimethyl-3-[[[5-(2-methyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-72-2 CAPLUS


CN 5-Heptenoic acid, 7-[(1S,2R,3R,5R)-6,6-dimethyl-3-[[[5-(2-thienyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-67-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-68-6 CAPLUS


CN 5-Heptenoic acid, 7-[(1S,2S,3S,5R)-6,6-dimethyl-3-[[[5-(1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-69-7 CAPLUS


CN 5-Heptenoic acid, 7-[(1S,2S,3S,5R)-6,6-dimethyl-3-[[[5-(3-thienyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.


RN 271774-73-3 CAPLUS

CN 5-Heptenoic acid, 7-[(1S,2R,3R,5R)-6,6-dimethyl-3-[[[5-(1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.


RN 271774-74-4 CAPLUS

CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 271774-75-5 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(2-thienylsulfonyl)-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-76-6 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(3-thienylsulfonyl)-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-77-7 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-[(2-methyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271774-81-3 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-[(2-thienylthio)methyl]-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-82-4 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(phenoxymethyl)-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-78-8 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(phenylmethyl)-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-80-2 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[4-(4-methoxyphenyl)benzoyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271774-83-5 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-[(phenylamino)methyl]-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-84-6 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-[(phenylthio)methyl]-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291744-50-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(1H-pyrrol-1-ylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291744-66-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-ethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291744-69-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-methylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291744-70-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-methylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291744-71-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-methylphenyl)thio]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291744-67-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,4-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291744-68-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methyl-2-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291744-72-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-furanylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291744-73-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-furanylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291744-74-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(benzo[b]thien-2-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
Double bond geometry as shown.




RN 291744-75-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-benzofuranylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291744-76-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1,1'-biphenyl)-4-ylmethyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291744-80-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(phenylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291744-81-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(phenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291744-82-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[7-(phenylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291744-77-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1,1'-biphenyl)-3-ylmethyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291744-78-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291744-79-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[6-(phenylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291744-83-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[[3-fluoro-4-(phenylmethoxy)phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291744-84-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[[3-fluoro-4-hydroxyphenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291744-85-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-hydroxy-4-(phenylmethoxy)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291744-87-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-phenylethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 thienyl]ethyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291744-91-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-(4-fluorophenyl)ethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291744-92-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3,5-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291744-88-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-(5-methyl-2-thienyl)ethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291744-89-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-(2-thienyl)ethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291744-90-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(2-thienyl)ethyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291744-93-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-fluorophenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291744-94-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-(trifluoromethyl)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291744-95-1 CAPLUS


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291744-96-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-naphthalenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291744-97-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-methoxyphenyl)ethyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-01-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-02-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(2-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-03-4 CAPLUS

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291744-98-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-(2-hydroxyphenyl)ethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291744-99-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[6-(phenylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-00-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(3-thienylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(3-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-05-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1-naphthalenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-06-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(1-naphthalenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-07-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[7-(2-thienylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-08-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(3-thienylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-11-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methylsulfonyl)phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291745-12-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[9H-fluoren-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291745-13-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-bromo-2,3-dihydro-7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-09-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[7-(3-furanylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291745-10-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methylthio)phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-14-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[7-(phenylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-15-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[7-(3-thienylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




IT 291745-16-9P 291745-17-0P 291745-18-1P
 291745-19-2P 291745-20-5P 291745-21-6P
 291745-23-8P 291745-24-9P 291745-25-0P
 291745-26-1P 291745-28-3P 291745-31-8P
 291745-32-9P 291745-33-0P 291745-34-1P
 291745-35-2P 291745-37-4P 291745-38-5P
 291745-39-6P 291745-40-9P 291745-41-0P
 291745-45-4P 291745-46-5P 291745-47-6P
 291745-48-7P 291745-51-2P 291745-52-3P
 291745-53-4P 291745-54-5P 291745-55-6P
 291745-56-7P 291745-59-0P 291745-60-3P
 291745-61-4P 291745-62-5P 291745-63-6P
 291745-64-7P 291745-65-8P 291745-66-9P
 291745-67-0P 291745-68-1P 291745-69-2P
 291745-70-3P 291745-71-6P 291745-72-7P
 291746-37-7P 291746-38-8P 291746-39-9P
 291746-40-2P 291746-41-3P 291746-42-4P
 291746-43-5P 291746-44-6P 291746-45-7P
 291746-46-8P 291746-47-9P 291746-48-0P
 291746-49-1P 291746-50-4P 291746-51-5P
 291746-52-6P 291746-53-7P 291746-54-8P
 291746-55-9P 291746-56-0P 291746-57-1P
 291746-58-2P 291746-59-3P 291746-60-6P
 291746-61-7P 291746-62-8P 291746-63-9P
 291746-64-0P 291746-65-1P 291746-66-2P
 291746-67-3P 291746-68-4P 291746-69-5P
 291746-70-8P 291746-71-9P 291746-72-0P
 291746-73-1P 291746-74-2P 291746-75-3P
 291746-76-4P 291746-77-5P 291746-78-6P
 291746-79-7P 291746-80-0P 291746-81-1P
 291746-82-2P 291746-83-3P 291746-84-4P
 291746-85-5P 291746-88-8P 291746-89-9P
 291746-90-2P 291746-91-3P 291746-92-4P
 291746-93-5P 291746-94-6P 291746-95-7P
 291746-96-8P 291746-97-9P 291746-98-0P
 291746-99-1P 291747-01-8P 291747-03-0P
 291747-04-1P 291747-05-2P 291747-06-3P

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-18-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(1,1'-biphenyl)-2-ylmethyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-19-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[9-oxo-9H-fluoren-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

291747-07-4P 291747-08-5P 291747-09-6P
 291747-10-9P 291747-12-1P 291747-14-3P
 291747-15-4P 291747-16-5P 291747-17-6P
 291747-18-7P 291747-19-8P 291747-20-1P
 291747-21-2P 291747-22-3P 291747-23-4P
 291747-24-5P 291747-25-6P 291747-26-7P
 291747-27-8P 291747-28-9P 291747-29-0P
 291747-31-6P 291747-32-7P 291749-94-5P
 380231-58-3P 380231-61-8P 380231-63-0P
 380231-65-2P 380231-66-3P 380231-67-4P
 380231-68-5P 380231-70-9P 380231-71-0P
 380231-72-1P 380231-73-2P 380231-74-3P
 380231-75-4P 380231-76-5P 380231-79-8P
 380231-84-5P 380231-87-8P 380231-90-3P
 380231-91-4P 380231-92-5P 380231-93-6P
 380232-00-8P 380232-01-9P 380232-02-0P
 380232-25-7P 380232-34-2P 380232-35-3P
 380232-56-4P 380232-57-5P 380233-64-7P

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of chiral heterocyclic carbonylaminobicycloheptanehydrocarbonarboxylic acids in remedy compn. as PGD2 and TXA2 receptors antagonists)
 RN 291745-16-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[7-[(4-methylphenyl)methyl]benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-17-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[7-(2-thienylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-20-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-21-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(benzo[b]thien-3-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-23-8 CAPLUS


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-hydroxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-24-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(9H-fluoren-3-yl)carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-25-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-fluorophenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

9

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291745-31-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-fluorophenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-32-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[[3-(trifluoromethyl)phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-33-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-chlorophenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-26-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-(phenylmethoxy)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-28-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-(phenylmethoxy)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-34-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,6-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-35-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[[2-(trifluoromethyl)phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-37-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dihydro-7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
(5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-38-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(benzo[b]thien-5-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291745-39-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(benzo[b]thien-6-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291745-45-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[10,11-dihydro-5-oxo-5H-dibenzof[a,d]cyclohept-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-46-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-fluorophenyl)methyl]-2-furanyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-47-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylmethyl)-2-furanyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-40-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(benzo[b]thien-7-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291745-41-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-hydroxybenzo[b]thien-3-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-48-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-51-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(3-dibenzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-52-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2,3-dimethoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-53-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methyl-3-isoxazolyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291745-54-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methoxy-4-methylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291745-59-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3,4-trimethoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-60-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-61-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3,4,5-trimethoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-55-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methoxybenzo[b]thien-3-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291745-56-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(9H-fluoren-2-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-62-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(1,3-benzodioxol-4-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-63-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-(acetylamino)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291745-64-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[[3-[(methylsulfonyl)amino]phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 291745-65-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dihydro-1,4-benzodioxin-5-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 291745-66-9 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methoxy-3-methylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 291745-69-2 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-dibenzothienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291745-70-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(9H-fluoren-1-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-67-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[[4-(acetylamino)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291745-68-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[[4-[(methylsulfonyl)amino]phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291745-71-6 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methoxy-3,4-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 291745-72-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-hydroxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-37-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(5-methyl-2-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291746-38-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-methylphenyl)thio]methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291746-39-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-methylphenyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291746-40-2 CAPLUS

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291746-43-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(benzo[b]thien-2-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-44-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(2-benzofuranyl-methyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291746-45-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(1,1'-biphenyl)-3-ylmethyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(4-methylphenyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-41-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(2-furanylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-42-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(3-furanylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291746-46-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(phenylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-47-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[6-(phenylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-48-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
(phenylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-49-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(phenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291746-50-4 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[7-(phenylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-53-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-methyl-2-thienyl)ethyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-54-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-(2-thienyl)ethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291746-55-9 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(2-(2-thienyl)ethyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-51-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(4-hydroxy-3-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291746-52-6 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-phenylethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-56-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(2-(4-fluorophenyl)ethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-57-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(phenylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291746-58-2 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
naphthalenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-59-3 CAPLUS
CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-2-[[[5-[2-(2-methoxyphenyl)ethyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291746-60-6 CAPLUS
CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-2-[[[5-[2-(2-hydroxyphenyl)ethyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
thienylmethyl]benzo[b]thien-2-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-64-0 CAPLUS
CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(2-thienylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-65-1 CAPLUS
CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[7-(3-thienylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291746-61-7 CAPLUS
CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(3-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291746-62-8 CAPLUS
CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[6-(phenylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291746-63-9 CAPLUS
CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(3-

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291746-66-2 CAPLUS
CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(3-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-67-3 CAPLUS
CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[7-(3-thienylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291746-68-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[4-(3-furanylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-69-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(1-naphthalenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-70-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(1-naphthalenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-73-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[8-oxo-8H-indeno[2,1-b]thien-2-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-74-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[7-(3-thienylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-71-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[7-(3-furanylmethyl)benzo[b]thien-3-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-72-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(9H-fluoren-2-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-75-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[7-(phenylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-76-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-methylphenylmethylbenzo[b]thien-2-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-77-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[7-(2-thienylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-78-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(1,1'-biphenyl)-2-ylmethyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291746-81-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(benzo[b]thien-3-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291746-82-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(4-hydroxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291746-83-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(9H-fluoren-3-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-79-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[9-oxo-9H-fluoren-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291746-80-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(4-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291746-84-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-fluorophenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291746-85-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[[4-(phenylmethoxy)phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 291746-88-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-fluorophenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-89-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(3-trifluoromethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-90-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-chlorophenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291746-93-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(5-bromo-2,3-dihydro-7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-94-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dihydro-7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291746-95-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(benzo[b]thien-6-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291746-91-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,6-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-92-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-trifluoromethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291746-96-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(benzo[b]thien-5-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-97-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(benzo[b]thien-7-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291746-98-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(5-hydroxybenzo[b]thien-3-

Page 37


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
dimethylbicyclo[3.1.1]hept-3-yl-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291747-12-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(9H-fluoren-2-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291747-14-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2,3,4-trimethoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-15-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291747-16-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(3,4,5-trimethoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-17-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(1,3-benzodioxol-4-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291747-18-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-(acetamido)phenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291747-19-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[[[3-[(methylsulfonyl)amino]phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291747-20-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(5-phenyl-2-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291747-21-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dihydro-1,4-benzodioxin-5-yl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291747-22-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-methoxy-3-methylphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291747-23-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(4-acetylaminophenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-26-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(9H-fluoren-1-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291747-27-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-methoxy-3,4-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-24-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[[4-[(methylsulfonyl)amino]phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291747-25-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(4-dibenzothiénylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-28-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(4-dibenzofuranylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291747-29-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-ethylphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-91-6 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(2-furanylmethyl)-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-92-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3R,4R)-3-[[[5-(3-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 380231-61-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[2-(1H-pyrrol-1-yl)-5-thiazolyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 380231-63-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(4-hydroxy-3-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 380231-65-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(3-furanylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291749-94-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(5-phenyl-2-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 380231-58-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-yl)sulfonyl]-2-furanyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 380231-66-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[[2-(ethenyl)oxy]phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 380231-67-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[[4-(ethenyl)oxy]phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 380231-68-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1,3-benzodioxol-5-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 380231-70-9 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-fluoro-4-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 380231-71-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-(hydroxymethoxy)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 380231-74-3 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-(dimethylaminomethoxy)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 380231-75-4 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-(1-methylethyl)amino)ethoxy]phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 380231-76-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(10,11-dihydro-5H-dibenzo[a,d]cyclohept-2-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 380231-72-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-(1-pyrrolidinylmethoxy)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 380231-73-2 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-[(dimethylamino)methoxy]phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 380231-79-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-dibenzofuran-2-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 380231-84-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[3-(1H-indol-1-yl)sulfonyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 380231-87-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(4-(ethenyl)oxy)phenyl]methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 380231-90-3 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-(1-pyrrolidinylmethyl)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 380231-91-4 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(10,11-dihydro-5-oxo-5H-dibenzo[a,d]cyclohepten-2-yl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 380232-00-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,2'-bithiophen)-5-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 380232-01-9 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-(acetoxy)phenyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 380232-02-0 CAPLUS

CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-phenyl-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 380231-92-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(5-methoxybenzo[b]thien-3-yl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 380231-93-6 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-2-yl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 380232-25-7 CAPLUS

CN 5-Hexenoic acid, 6-[(1R,2R,3S,4S)-3-[[[5-[(1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 380232-54-2 CAPLUS

CN 5-Heptenoic acid, 2-methyl-7-[(1R,2S,3S,4S)-3-[[[5-[(1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

RN 380232-55-3 CAPLUS

CN 5-Heptenoic acid, 2,2-dimethyl-7-[(1R,2S,3S,4S)-3-[[[5-[(1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)-

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 380232-56-4 CAPLUS

CN 5-Heptenoic acid, 2,2-dimethyl-7-[(1R,2S,3S,4S)-3-[[[5-(3-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 380232-57-5 CAPLUS

CN 5-Heptenoic acid, 7-[[[5-[(2-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-2,2-dimethyl-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 380233-64-7 CAPLUS

CN 5-Heptenoic acid, 7-[[[5-[(2-methyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-2-methyl-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 3 OF 17 CAPLUS COPYRIGHT 2003 ACS

2001:713115 CAPLUS

DN 135:262245

TI Enteric granular compositions of hardly-water soluble drugs characterized by containing water-repellent components

IN Tsukada, Takayuki; Syodai, Hidekazu; Sezaki, Hajime; Suzuki, Yusuke

PA Shionogi & Co., Ltd., Japan

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001070201	A1	20010927	WO 2001-JP2152	20010319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001041192	A5	20011003	AU 2001-41192	20010319
EP 1266655	A1	20021218	EP 2001-912475	20010319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRAI JP 2000-81354 A 20000323

WO 2001-JP2152 W 20010319

AB It is found out that the burst phenomenon due to the digestive tract movement can be prevented and thus the release of a drug can be controlled without worsening the dissoln. properties of the drug by adding a water-repellent component to an enteric layer, a lower coating layer and/or an upper coating layer. Enteric granules consisting base granules contg. (Z)-7-[(1R,2R,3S,5S)-2-[(5-hydroxybenzo[b]thiophene-3-ylcarbonyl)amino]-10-norpinane-3-yl]-5-heptenoic acid 100, D-mannitol 44, low-substituted hydroxypropyl cellulose (L-HPC31) 8, hydroxypropyl cellulose (HPC-SL) 8 parts, lower coating layers contg. talc 10, hydroxypropyl Me cellulose (HPMC2910 RW) 4.5, stearyl alc. 0.95 parts, and enteric layers contg. hydroxypropyl Me cellulose acetate succinate (HPMCAS-LF) 51.29, tri-Et citrate 10.26, talc 15.39, sodium lauryl sulfate 1.54 parts were prepd.


IT 209268-36-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enteric granular compns. of hardly-water sol. drugs contg. water-repellent components)

RN 209268-36-0 CAPLUS

CN 5-Heptenoic acid, 7-[[[5-[(2-methyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


ANSWER 4 OF 17 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:546908 CAPLUS
 DN 135:327105
 TI Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751
 AU Arimura, Akinori; Yasui, Kiyoshi; Kishino, Junji; Asanuma, Fujio; Hasegawa, Hiroshi; Kakudo, Shinji; Ohtani, Mitsuaki; Arita, Hitoshi
 CS Discovery Research Laboratories, Shionogi and Co., Osaka, Japan
 SO Journal of Pharmacology and Experimental Therapeutics (2001), 298(2), 411-419
 CODEN: JPETAB; ISSN: 0022-3565
 PB American Society for Pharmacology and Experimental Therapeutics
 DT Journal
 LA English
 AB Prostaglandin (PG) D2, the major cyclooxygenase metabolite generated from immunol. stimulated mast cells, is thought to contribute to the pathogenesis of allergic diseases due to its various inflammatory effects. However, since no DP receptor antagonist has been developed as an antiallergic drug, the role of PGD2 in the pathogenesis of allergic diseases remains uncertain. Here, we report the in vivo efficacy of our newly established DP receptor antagonist, S-5751 [(2)-7-[(1R,2R,3S,5S)-2-(5-hydroxybenzo[b]thiophen-3-ylcarbonylamino)-10-norpinan-3-yl]hept-5-enoic acid], using various allergic inflammation guinea pig models. In allergic rhinitis models, oral administration of S-5751 dramatically inhibited not only early nasal responses, as assessed by sneezing, mucosal plasma exudation, and nasal blockage, but also late responses such as mucosal plasma exudation and eosinophil infiltration. Even when S-5751 was administered after recovery from the early responses, these late phase responses were almost completely suppressed. In addn., S-5751 alleviated allergen-induced plasma exudation in the conjunctiva in an allergic conjunctivitis model and antigen-induced eosinophil infiltration into the lung in an asthma model. These findings provide evidence for the crucial role of PGD2 as a mediator of allergic inflammation in guinea pigs and suggest that DP receptor antagonists may be useful in the treatment of allergic diseases triggered by mast cell activation.
 IT 209268-36-0, S 5751
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (prevention of allergic inflammation by a prostaglandin receptor antagonist, S-5751)
 RN 209268-36-0 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-2-[[[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


ANSWER 5 OF 17 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:31442 CAPLUS
 DN 134:101033
 TI Process for producing bicyclic amino alcohol from (+)-nopinone
 AU Honma, Taunetosshi; Hiratsubo, Yoshiharu; Mitsumori, Susumu
 CS Shionogi & Co., Ltd., Japan
 SO PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001002334	A1	20010111	WO 2000-JP4171	20000626
W: AZ, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AH, AZ, BY, BG, KZ, MD, RU, TJ, TM, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, CA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1193243	A1	20020403	EP 2000-939160	20000626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI JP 1999-188674	A	19990702	WO 2000-JP4171	20000626
OS CASREACT 134:101033; MARPAT 134:101033				
GI				




AB The bicyclic amino alc. I is prepd. by reaction of (+)-nopinone with XCH2CO2R1 (X = halo; R1 = alkyl) in the presence of an additive and a base, followed by conversion of the product into an oxime, and redn. of the oxime. I is then converted in several steps to a known PGD2 antagonist.
 IT 209268-36-0P
 RI: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (PGD2 antagonist; process for producing bicyclic amino alc. from (+)-nopinone)
 RN 209268-36-0 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-2-[[[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 244246-69-3P
 RI: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (process for producing bicyclic amino alc. from (+)-nopinone)
 RN 244246-69-3 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[(5-[(phenylsulfonyl)oxy]benzo[b]thien-3-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.
 Double bond geometry as shown.

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS

AN 2000:645983 CAPLUS

DN 133:222579

TI Preparation of [2.2.1] and [3.1.1]bicycloheptane antagonistic to both of

PGD2/TXA2 receptors

IN Honma, Tsunetoshi; Hiramatsu, Yoshiharu; Arimura, Akinori

PA Shionogi and Co., Ltd., Japan

SO PCT Int. Appl., 251 pp.



CODEN: F1XXD2

DT Patent

LA Japanese

FAN: CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000053573	A1	20000914	WO 2000-JP1223	20000302
V: AB, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CE, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MX, MN, MW, MY, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1176139	A1	20020130	EP 2000-906622	20000302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI JP 1999-62721	A	19990310		
WO 2000-JP1223	W	20000302		
OS MARPAT 133:222579				
GI				



AB Medicinal compns. contg. the title compds. [I: ring Y = Q, Q1, Q2; R1 = CH2CH2CH(CH2)3CO2R2; CH:CH(CH2)3CO2R2; wherein R2 = H, alkyl; m = 0,1; p =

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

0,1; when p = 0, X1 and X3 are not linked to each other through X4; X1, X3 = (un)substituted aryl or heteroaryl; X2 = CH2, CH2CH2, CO, O, S, SO, SO2, NH, NMe, C(=NOMe), N,N, CH:CH, CONH, NHCO, CH2NH, NHCH2, CH2O, OCH2, CH2S, SCH2, CH2SO2, SO2CH2, SO2NH, NHSO2; X4 = CH2, CH2CH2, CO, SO, SO2, CONH, NHCO, CH2NH, NHCH2, CH2O, OCH2, CH2S, SCH2, CH2SO2, SO2CH2, SO2NH, NHSO2), prodrugs or pharmaceutically acceptable salts thereof, or hydrate thereof antagonistic to both of thromboxane A2 and prostaglandin D2 receptors and medicinal compns. for the treatment of asthma and nasal obstruction are claimed. Thus, (5Z)-7-[(1R,2S,3S,4S)-3-aminobicyclo[2.2.1]hept-2-yl]-5-heptenoic acid Me ester was condensed with 5-(pyrrole-1-sulfonyl)thiophene-2-carboxylic acid using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1-hydroxybenzotriazole in THF under ice-cooling at 25 degree. for 16 h, followed by sapon. with a mixt. of 4 N aq. NaOH and THF and acidification with 5 N aq. HCl to give title compd. [II]; R = 5-(pyrrole-1-sulfonyl)thiophene-2-carbonyl [III]. III and II [R = 2-(thiophen-2-ylthiomethyl)thiophen-5-yl] showed IC50 of 0.0043 and 0.001 .mu.M. resp., for inhibiting the binding the [3H](+)-(5Z)-7-[3-endo-(phenylsulfonylamino)bicyclo[2.2.1]hept-2-yl]heptenoic acid sodium salt to prostaglandin D2 receptor prepn. from human peripheral blood platelet.

IT 186532-87-6P	271772-82-8P	271772-88-4P
271772-90-8P	271772-92-0P	271772-94-2P
271772-95-3P	271772-96-4P	271772-97-5P
271772-98-6P	271772-99-7P	271773-00-3P
271773-01-4P	271773-02-5P	271773-03-6P
271773-04-7P	271773-05-8P	271773-06-9P
271773-07-0P	271773-08-1P	271773-09-2P
271773-10-5P	271773-11-6P	271773-12-7P
271773-13-8P	271773-14-9P	271773-15-0P
271773-16-1P	271773-17-2P	271773-18-3P
271773-19-4P	271773-20-7P	271773-21-8P
271773-22-9P	271773-23-0P	271773-24-1P
271773-25-2P	271773-26-3P	271773-27-4P
271773-28-5P	271773-29-6P	271773-30-9P
271773-31-0P	271773-32-2P	271773-34-3P
271773-35-4P	271773-36-5P	271773-37-6P
271773-38-7P	271773-39-8P	271773-40-1P
271773-41-2P	271773-42-3P	271773-43-4P
271773-44-5P	271773-45-6P	271773-46-7P
271773-47-8P	271773-48-9P	271773-49-0P
271773-50-3P	271773-51-4P	271773-52-5P
271773-53-6P	271773-54-7P	271773-55-8P
271773-56-9P	271773-57-0P	271773-58-1P
271773-59-2P	271773-60-5P	271773-61-6P
271773-62-7P	271773-63-8P	271773-64-9P
271773-65-0P	271773-66-1P	271773-69-4P
271773-70-7P	271773-71-8P	271773-72-9P
271773-73-0P	271773-74-1P	271773-75-2P
271773-76-3P	271773-77-4P	271773-78-5P
271773-79-6P	271773-80-9P	271773-81-0P
271773-82-1P	271773-83-2P	271773-84-3P
271773-85-4P	271773-86-5P	271773-87-6P
271773-88-7P	271773-89-8P	271773-90-1P
271773-91-2P	271773-92-3P	271773-94-5P

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

271773-95-6P	271773-96-7P	271773-97-8P
271773-98-9P	271773-99-0P	271774-00-6P
271774-01-7P	271774-02-8P	271774-03-9P
271774-04-0P	271774-05-1P	271774-06-2P
271774-07-3P	271774-08-4P	271774-09-5P
271774-10-8P	271774-11-9P	271774-13-1P
271774-14-2P	271774-15-3P	271774-16-4P
271774-17-5P	271774-18-6P	271774-19-7P
271774-20-0P	271774-21-1P	271774-22-2P
271774-23-3P	271774-24-4P	271774-25-5P
271774-26-6P	271774-27-7P	271774-28-8P
271774-29-9P	271774-30-2P	271774-32-4P
271774-33-5P	271774-35-7P	271774-36-8P
271774-37-9P	271774-38-0P	271774-39-1P
271774-40-4P	271774-41-5P	271774-42-6P
271774-43-7P	271774-44-8P	271774-45-9P
271774-46-0P	271774-47-1P	271774-48-2P
271774-49-3P	271774-50-6P	271774-52-8P
271774-53-9P	271774-54-0P	271774-55-1P
271774-56-2P	271774-57-3P	271774-58-4P
271774-59-5P	271774-60-8P	271774-61-9P
271774-62-0P	271774-63-1P	271774-64-2P
271774-65-3P	271774-66-4P	271774-67-5P
271774-68-6P	271774-69-7P	271774-70-0P
271774-71-1P	271774-72-2P	271774-74-4P
271774-75-5P	271774-76-6P	271774-77-7P
271774-78-8P	271774-79-9P	271774-80-2P
271774-81-3P	271774-82-4P	271774-83-5P
271774-84-6P	271774-85-7P	271774-86-8P
271774-87-9P	271774-88-0P	271774-89-1P
271774-90-4P	271774-91-5P	271774-92-6P
271774-93-7P	271774-94-8P	271774-95-9P
271774-96-0P	271774-97-1P	271774-98-2P
271774-99-5P	271775-00-6P	271775-01-7P
271775-02-8P	271775-03-9P	271775-04-0P
271775-05-1P	271775-06-2P	271775-07-3P
271775-08-4P	271775-09-5P	271775-10-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of [2.2.1] and [3.1.1]bicycloheptane as antagonists of PGD2/TXA2 receptors for treatment of asthma and nasal obstruction)

RN 186532-87-6 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[(4-phenylthio)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, monosodium salt, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271772-82-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1S,2R,3R,4R)-3-[(1,1'-biphenyl)-4-ylcarbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI). (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 271772-88-4 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[(5-(3-hydroxyphenyl)-3-thienyl)carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271772-90-8 CAPLUS


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(4-methoxyphenyl)thio]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271772-92-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[3-[(4-methoxyphenyl)thio]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271772-94-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-(1H-pyrrol-1-yl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271772-97-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-(benzoylamino)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271772-98-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-(1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271772-99-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-(phenylmethyl)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271772-95-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(phenylamino)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271772-96-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-[(phenylsulfonyl)amino]-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-00-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(phenylsulfonyl)amino]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-01-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-[(phenylamino)sulfonyl]-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-02-5 CAPLUS


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-ylsulfonyl)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-03-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(1H-pyrrol-1-ylsulfonyl)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-04-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[3-methyl-1H-pyrrol-1-yl]sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-07-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(1H-pyrrol-1-ylmethyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-08-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(1H-indol-1-ylsulfonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-05-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[3-(1H-pyrrol-1-ylsulfonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-06-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(2-methyl-1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271773-09-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[[2-(hydroxymethyl)-1H-pyrrol-1-yl]sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-10-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(2-thiazolylamino)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-11-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(2-thiazolylamino)carbonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-12-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-yl)sulfonyl]benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271773-13-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(2-thienylthio)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-16-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(3-thienylthio)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271773-17-2 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(3-thienylthio)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-14-9 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(2-thienylthio)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271773-15-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(2-pyridinylthio)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-18-3 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(2-furanylthio)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271773-19-4 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(2-thienylthio)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 271773-20-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(2-thienylthio)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 271773-21-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-ylsulfonyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 271773-22-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-ylsulfonyl)-2-furanyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-23-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271773-24-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylthio)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271773-25-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 271773-26-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(benzoylamino)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 271773-27-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-28-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-phenyl-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271773-29-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-benzoyl-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 271773-30-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[2,3'-bithiophen]-5-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

18 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-31-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[2,2'-bithiophen]-5-ylcarbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-33-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(4-methylphenyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-34-3 CAPLUS

18 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-37-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-imidazol-1-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-38-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrazol-1-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-39-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(phenylsulfonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


18 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-35-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(4-fluorophenyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-36-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

18 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-40-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(4-methoxyphenyl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-41-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(2-thienylcarbonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271773-42-3 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 271773-43-4 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-yl)-4-(1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 271773-44-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-methyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-methyl-5-(1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 271773-48-9 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271773-49-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(phenylthio)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-45-6 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(benzoylamino)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 271773-46-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 271773-47-8 CAPLUS

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-50-3 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenoxy-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271773-51-4 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[6-(1H-pyrrol-1-yl)sulfonyl]benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271773-52-5 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[2-(benzoylamino)-4-methyl-5-thiazolyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-53-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-methyl-2-[(phenylsulfonyl)amino]-5-thiazolyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-54-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-methyl-6-phenylimidazo[2,1-b]thiazol-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-57-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-thienylamino)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-58-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(3-thienylamino)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-59-2 CAPLUS

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-55-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(2-thienylmethyl)thio]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-56-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(2-thienylmethyl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(phenylamino)carbonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-60-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[[[4-fluorophenyl]amino]carbonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-61-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[[[4-methoxyphenyl]amino]carbonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 271773-62-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3,4,5-trimethoxyphenyl)amino]carbonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-63-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-yl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-64-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(2-thienylthio)methyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-69-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(3-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-70-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(3-thienylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-71-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(5-methyl-2-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-65-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(2-thienylsulfonyl)methyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-66-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylthio)methyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-72-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(5-methyl-2-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-73-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[2-(2-thienylthio)-4-thiazolyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-74-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(phenylmethyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
Double bond geometry as shown.




RN 271773-75-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-(2-thienylmethyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-76-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-(2-thienylmethyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-80-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1-(2-thienylmethyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-81-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1-(3-thienylmethyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-82-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1-(phenylsulfonyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271773-77-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-(3-thienylmethyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-78-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(3-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-79-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1-(phenylmethyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-83-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-84-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1-(2-thienylsulfonyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-85-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1-(1H-pyrrol-1-yl)-4-thiazolyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-86-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylthio)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-87-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylsulfonyl)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-88-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(1E)-2-(3-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-91-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methyl-3-thienyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-92-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(1Z)-2-(2-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-94-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-thienylthio)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-89-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(1Z)-2-(3-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-90-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methyl-3-thienyl)thio]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-95-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-thienylsulfonyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-96-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-thienylmethyl)thio]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-97-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-thienylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.
Double bond geometry as shown.




RN 271773-98-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methyl-2-thienyl)sulfinyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 271773-99-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienyl)sulfinyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-01-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-((phenylamino)-2-thienyl)sulfinyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-02-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-((methylphenylamino)-2-thienyl)sulfinyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-03-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-((3-methylphenylthio)-2-thienyl)sulfinyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271774-00-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(methoxyimino)-2-thienylmethyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 271774-01-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-((phenylamino)-2-thienyl)sulfinyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-02-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-((methylphenylamino)-2-thienyl)sulfinyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-06-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-((3-methoxyphenyl)sulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-07-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-((3-hydroxyphenyl)sulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 271774-08-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-hydroxyphenyl)thio]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-09-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-10-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-hydroxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 271774-14-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenoxymethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-15-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(phenylamino)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-16-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-11-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-(4-acetoxypheyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-13-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(phenylthio)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-17-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-18-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(phenylsulfonyl)amino]-3-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-19-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(benzoylamino)-3-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-20-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[5-(phenylmethyl)-3-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-21-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[4-(1H-pyrrol-1-yl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271774-22-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[4-[(phenylamino)sulfonyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-23-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[4-[(phenylsulfonyl)amino]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-24-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[4-(1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-25-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[2-phenylbenzo[b]thien-5-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-26-6 CAPLUS

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[3-[(1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-27-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[4-[(2-methyl-1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-28-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[4-(1H-pyrrol-1-yl)methyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-29-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[4-(1H-indol-1-yl)sulfonyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-30-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(1H-pyrrol-1-yl)sulfonyl]-3-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-36-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[1-(phenylsulfonyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-37-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-38-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(5-methyl-2-thienyl)thio]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271774-32-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[4-[(2-hydroxymethyl)-1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-33-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(1H-pyrrol-1-yl)sulfonyl]-3-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-35-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[1-(2-thienylsulfonyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-39-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(5-methyl-2-thienyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-40-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[1-[(4-fluorophenyl)sulfonyl]-1H-pyrrol-3-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-41-5 CAPLUS


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[1-(4-methoxyphenyl)sulfonyl]-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-42-6 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-thienyl)-1H-pyrrol-2-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-43-7 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(1E)-2-(3-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(5-methyl-3-thienyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-47-1 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(phenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-48-2 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(1Z)-2-(2-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-44-8 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(1Z)-2-(3-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-45-9 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(5-methyl-3-thienyl)thio]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-46-0 CAPLUS

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271774-49-3 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(1E)-2-(2-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-50-6 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-methyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-52-8 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-thienylsulfinyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-53-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-methyl-2-thienyl)sulfinyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-54-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-55-1 CAPLUS

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-58-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(3-methylphenyl)thio]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-59-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(3-methoxyphenyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-60-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(3-methoxyphenyl)thio]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-hydroxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-56-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-acetoxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-57-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(phenylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-61-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-methoxyphenyl)sulfonyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-62-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-hydroxyphenyl)sulfonyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 271774-63-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-hydroxyphenyl)thio]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-64-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-65-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(methylphenylamino)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1S,2S,3S,5R)-6,6-dimethyl-3-[[[5-(1H-pyrrol-1-ylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-69-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1S,2S,3S,5R)-6,6-dimethyl-3-[[[5-(3-thienylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-70-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1S,2S,3S,5R)-6,6-dimethyl-3-[[[5-(2-thienylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-71-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1S,2S,3S,5R)-6,6-dimethyl-3-[[[5-(2-methyl-1H-pyrrol-1-ylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-66-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-methylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-67-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-68-6 CAPLUS


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-72-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1S,2R,3R,5R)-6,6-dimethyl-3-[[[5-(2-thienylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



RN 271774-74-4 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(1H-pyrrol-1-ylsulfonyl)-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271774-75-5 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(2-thienylsulfonyl)-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-76-6 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(3-thienylsulfonyl)-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-77-7 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-[(2-methyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271774-80-2 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[4-(4-methoxyphenoxy)benzoyl]amino]ethyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-81-3 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-[(2-thienylthio)methyl]-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-78-8 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(phenylmethyl)-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-79-9 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(phenyl)-3-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271774-82-4 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(phenoxymethyl)-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-83-5 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-[(phenylamino)methyl]-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271774-84-6 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-[(phenylthio)methyl]-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291744-50-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrcol-1-ylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291744-67-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,4-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291744-68-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methyl-2-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291744-62-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[[2-(hydroxymethyl)-1H-pyrcol-1-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291744-63-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[[2-(2-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.




RN 291744-66-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-ethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291744-69-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-methylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291744-70-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-methylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291744-71-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-methylphenylthio)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291744-72-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-furanylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291744-73-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(3-furanylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291744-74-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(benzo[b]thien-2-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291744-77-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-([1,1'-biphenyl]-3-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291744-78-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291744-79-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[6-(phenylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291744-75-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-benzofuranylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291744-76-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-([1,1'-biphenyl]-4-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291744-80-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(phenylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291744-81-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(phenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291744-82-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[7-(phenylmethyl)benzo[b]thien-3-

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291744-83-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-fluoro-4-(phenylmethoxy)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291744-84-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-fluoro-4-hydroxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291744-87-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-phenylethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291744-88-2 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-(5-methyl-2-thienyl)ethyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291744-89-3 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-(2-thienyl)ethyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Page 66


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291744-85-9 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-hydroxy-4-(phenylmethoxy)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291744-86-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-hydroxy-4-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291744-90-6 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(2-(2-thienyl)ethyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291744-91-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-(4-fluorophenyl)ethyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291744-92-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3,5-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291744-93-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-fluorophenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291744-94-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-(trifluoromethyl)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-hydroxyphenyl)ethyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291744-98-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-hydroxyphenyl)ethyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291744-99-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[6-(phenylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-00-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(3-thienylmethyl)benzo[b]thien-2-

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291744-95-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291744-96-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-naphthalenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291744-97-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[2-(2-methoxyphenyl)ethyl]-2-


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-thienylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-01-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-02-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(2-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 291745-03-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(3-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-04-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(2-furanylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-05-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1-naphthalenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-06-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(1-naphthalenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-07-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[7-(2-thienylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-08-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[7-(3-thienylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-09-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[7-(3-furanylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 291745-10-3P 291745-11-4P 291745-12-5P
 291745-13-6P 291745-14-7P 291745-15-8P
 291745-16-9P 291745-17-0P 291745-18-1P
 291745-19-2P 291745-20-5P 291745-21-6P
 291745-23-8P 291745-24-9P 291745-25-0P
 291745-26-1P 291745-27-2P 291745-28-3P
 291745-29-4P 291745-30-7P 291745-31-8P
 291745-32-9P 291745-33-0P 291745-34-1P
 291745-35-2P 291745-36-3P 291745-37-4P
 291745-38-5P 291745-39-6P 291745-40-9P
 291745-41-0P 291745-42-1P 291745-43-2P
 291745-44-3P 291745-45-4P 291745-46-5P
 291745-47-6P 291745-48-7P 291745-49-8P
 291745-50-1P 291745-51-2P 291745-52-3P
 291745-53-4P 291745-54-5P 291745-55-6P
 291745-56-7P 291745-57-8P 291745-59-0P
 291745-60-3P 291745-61-4P 291745-62-5P
 291745-63-6P 291745-64-7P 291745-65-8P
 291745-66-9P 291745-67-0P 291745-68-1P
 291745-69-2P 291745-70-5P 291745-71-6P
 291745-72-7P 291745-73-8P 291745-74-9P
 291745-75-0P 291745-76-1P 291745-77-2P
 291745-78-3P 291745-79-4P 291745-80-7P
 291745-81-0P 291745-82-9P 291745-83-0P
 291745-84-1P 291745-85-2P 291745-86-3P
 291745-87-4P 291745-88-5P 291745-89-6P
 291745-90-9P 291745-91-0P 291745-92-1P
 291745-93-2P 291745-94-3P 291745-95-4P
 291745-96-5P 291745-97-6P 291745-98-7P
 291745-99-8P 291746-01-5P 291746-02-6P
 291746-03-7P 291746-04-8P 291746-05-9P
 291746-06-0P 291746-07-1P 291746-08-2P
 291746-09-3P 291746-10-6P 291746-11-7P
 291746-12-8P 291746-13-9P 291746-14-0P
 291746-15-1P 291746-16-2P 291746-17-3P
 291746-18-4P 291746-19-5P 291746-20-8P
 291746-21-9P 291746-22-0P 291746-23-1P
 291746-24-2P 291746-25-3P 291746-26-4P
 291746-27-5P 291746-28-6P 291746-29-7P
 291746-30-0P 291746-31-1P 291746-32-2P
 291746-33-3P 291746-34-4P 291746-35-5P


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

291746-36-6P 291746-37-7P 291746-38-8P
 291746-39-9P 291746-40-2P 291746-41-3P
 291746-42-4P 291746-43-5P 291746-44-6P
 291746-45-7P 291746-46-8P 291746-47-9P
 291746-48-0P 291746-49-1P 291746-50-4P
 291746-51-5P 291746-52-6P 291746-53-7P
 291746-54-8P 291746-55-9P 291746-56-0P
 291746-57-1P 291746-58-2P 291746-59-3P
 291746-60-5P 291746-61-7P 291746-62-8P
 291746-63-9P 291746-64-0P 291746-65-1P
 291746-66-2P 291746-67-3P 291746-68-4P
 291746-69-5P 291746-70-8P 291746-71-9P
 291746-72-0P 291746-73-1P 291746-74-2P
 291746-75-3P 291746-76-4P 291746-77-5P
 291746-78-6P 291746-79-7P 291746-80-0P
 291746-81-1P 291746-82-2P 291746-83-3P
 291746-84-4P 291746-85-5P 291746-86-6P
 291746-87-7P 291746-88-8P 291746-89-9P
 291746-90-2P 291746-91-3P 291746-92-4P
 291746-93-5P 291746-94-6P 291746-95-7P
 291746-96-8P 291746-97-9P 291746-98-0P
 291746-99-1P 291747-00-7P 291747-01-8P
 291747-02-9P 291747-03-0P 291747-04-1P
 291747-05-2P 291747-06-3P 291747-07-4P
 291747-08-5P 291747-09-6P 291747-10-9P
 291747-11-0P 291747-12-1P 291747-13-2P
 291747-14-3P 291747-15-4P 291747-16-5P
 291747-17-6P 291747-18-7P 291747-19-8P
 291747-20-1P 291747-21-2P 291747-22-3P
 291747-23-4P 291747-24-5P 291747-25-6P
 291747-26-7P 291747-27-8P 291747-28-9P
 291747-29-0P 291747-30-3P 291747-31-4P
 291747-32-5P 291747-33-6P 291747-34-7P
 291747-35-8P 291747-36-9P 291747-37-0P
 291747-38-1P 291747-39-2P 291747-40-5P
 291747-41-6P 291747-42-7P 291747-43-8P
 291747-44-9P 291747-45-0P 291747-46-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of [2.2.1] and [3.1.1]bicycloheptane as antagonists of PGD₂/TXA₂ receptors for treatment of asthma and nasal obstruction)


RN 291745-10-3 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2S,3S,4S)-3-[[[5-[[2-(methylthio)phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-14-7 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2S,3S,4S)-3-[[[7-(phenylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-15-8 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2S,3S,4S)-3-[[[7-(3-thienylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-11-4 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2S,3S,4S)-3-[[[5-[[2-(methylthio)phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-12-5 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2S,3S,4S)-3-[[[9H-fluoren-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-13-6 CAPLUS

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-16-9 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2S,3S,4S)-3-[[[7-[(4-methylphenyl)methyl]benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-17-0 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2S,3S,4S)-3-[[[7-(2-thienylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-18-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(1,1'-biphenyl)-2-ylmethyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-19-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[9-oxo-9H-fluoren-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-23-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-hydroxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-24-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[9H-fluoren-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-25-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-fluorophenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-20-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-21-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(benzo[b]thien-3-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-26-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-phenylmethoxy)phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-27-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-propenyloxy)phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 291745-28-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-(phenylmethoxy)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-29-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-(2-propenyloxy)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-30-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(1,3-benzodioxol-5-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 291745-33-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-chlorophenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-34-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,6-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-35-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-(trifluoromethyl)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-31-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-fluorophenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-32-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-(trifluoromethyl)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-36-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-fluoro-3-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-37-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dihydro-7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 291745-38-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(benzo[b]thien-5-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-39-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(benzo[b]thien-6-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-40-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(benzo[b]thien-7-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-43-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-(1-pyrrolidinylmethyl)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-44-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-(dimethylamino)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-41-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-hydroxybenzo[b]thien-3-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-42-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-(hydroxymethyl)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-45-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(10,11-dihydro-5-oxo-5H-dibenzo[a,d]cyclohept-2-yl)carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-46-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-fluorophenyl)methyl]-2-furanyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-47-6 CAPLUS


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-48-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(7-benzofuranylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-49-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methylphenylamino)methyl]phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 291745-52-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dimethoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-53-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methyl-3-isoxazolyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-54-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methoxy-4-methylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-50-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(1-methyl-2-phenylamino)methyl]phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-51-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-dibenzofuranylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-55-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methoxybenzo[b]thien-3-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-56-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(9H-fluoren-2-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-57-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-2-yl)carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 291745-59-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3,4-trimethoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 291745-60-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-63-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-(acetamino)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291745-64-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-(methylsulfonyl)amino)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291745-65-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dihydro-1,4-benzodioxin-5-

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-61-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3,4,5-trimethoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 291745-62-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(1,3-benzodioxol-4-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 ylmethyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 291745-66-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methoxy-3-methylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291745-67-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-(acetamino)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-68-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-methylsulfonyl)amino]bicyclo[2.2.1]hept-2-ylidene]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-69-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-dimethylthienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-ylidene]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-72-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-hydroxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-ylidene]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-73-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methoxy-3,5-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-ylidene]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-70-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(9H-fluoren-1-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-ylidene]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-71-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methoxy-3,4-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-ylidene]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291745-74-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methoxy-3,4-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-ylidene]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-75-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methoxy-4,6-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-ylidene]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-76-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-benzofuranylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-ylidene]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-77-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methoxy-3-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 291745-78-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-hydroxy-3-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-82-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(6-hydroxy-3-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-83-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(6-fluoro-3-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-84-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(6-methyl-3-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291745-79-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-fluoro-3-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291745-80-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methyl-3-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-81-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(6-methoxy-3-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


(5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291745-85-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(1,2-benzisoxazol-3-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 291745-86-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methoxy-1,2-benzisoxazol-3-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



18 ANSWER 6 OF 17 CAPIUS COPYRIGHT 2003 ACS (Continued)


RN 291745-87-4 CAPLUS
CN 5-Heptenoic acid, 7-([1R,2S,3S,4S)-3-[[[5-[(5-hydroxy-1,2-benzisoxazol-3-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (CA INDEX - 9CI)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-88-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(5-fluoro-1,2-benzisoxazol-3-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-89-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[{5-[(5-methyl-1,2-benzisoxazol-3-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-92-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[[4-(4-methoxyphenyl)-2-thienyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-93-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(4-hydroxyphenyl)-2-thienyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl], (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPIUS COPYRIGHT 2003 ACS (Continued)



RN 291745-90-9 CAPLUS
CN 5-Heptenoic acid, 7-([1R,2S,3S,4S]-3-[[5-[(5-chloro-4-phenyl-2-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl)-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-91-0 CAPLUS
CN 5-Heptenoic acid, 7-([1R,2S,3S,4S]-3-[[[5-[(4-phenyl-2-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-94-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-[[4-(4-fluorophenyl)-2-thienyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291745-95-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-[[4-(4-methylphenyl)-2-thienyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl)-, (5Z)-
(9ci) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291745-96-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-chloro-2-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291745-97-6 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-phenyl-3-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291746-01-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thiazolylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-02-6 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-benzothiazolylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-03-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(3-pyridinylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291745-98-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-phenyl-3-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 291745-99-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-phenylmethyl)-3-thienyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 291746-04-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(7-isoquinolinylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-05-9 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(6-isoquinolinylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-06-0 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dihydro-4-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-07-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dihydro-6-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-08-2 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dihydro-5-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291746-11-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-methyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-12-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-(1H-pyrrol-1-yl)sulfonyl)-2-thienyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-13-9 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291746-09-3 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,4-difluorophenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-10-6 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,5-dimethyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291746-14-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-thienylsulfonyl)-2-thienyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-15-1 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(6-hydroxy-2-naphthalenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 291746-16-2 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(1-hydroxy-2-naphthalenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 291746-17-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(6-hydroxy-1-naphthalenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 291746-18-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-thienyl)methyl]phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-21-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dihydrothieno[3,2-b]furan-5-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-22-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dihydrothieno[3,2-b]furan-6-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-23-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-fluoro-2,3-dihydro-7-

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291746-19-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-(1H-pyrrol-1-yl)sulfonyl)phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 291746-20-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methyl-1H-pyrrol-1-yl)sulfonyl]phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 291746-24-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-chloro-2,3-dihydro-7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-25-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dihydro-5-methyl-7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-26-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dihydro-5-hydroxy-7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-27-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dihydro-4-phenyl-7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-30-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[7-(phenylmethyl)-3-benzofuranyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-31-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[7-(3-thienylmethyl)-3-benzofuranyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-28-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dihydrothieno[3,4-b]furan-6-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-29-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2,3-dihydro-4-methylthieno[3,4-b]furan-6-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-32-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[7-(2-thienylmethyl)-3-benzofuranyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-33-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[7-(3-furanyl)methyl]-3-benzofuranyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-34-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[7-(2-furanylmethyl)-3-benzofuranyl]carbonyl]amino]bicyclo[2.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-35-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(1H-pyrrol-1-ylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291746-38-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(3-methylphenyl)thio]methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291746-39-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-methylphenyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291746-40-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(4-methylphenyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-36-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(2-thienylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-37-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(5-methyl-2-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291746-41-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-furanylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-42-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(3-furanylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-43-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(benzo[b]thien-2-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
(CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-44-6 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(2-benzofuranylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-45-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(1,1'-biphenyl-3-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 291746-48-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(phenylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-49-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(phenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291746-50-4 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[7-(phenylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-46-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(phenylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291746-47-9 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[6-(phenylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-51-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(4-hydroxy-3-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-52-6 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-phenylethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291746-53-7 CAPLUS

CN 5-Heptenoic acid, 7-[[[1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-(5-methyl-2-thienyl)ethyl]-2-thienyl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-54-8 CAPLUS

CN 5-Heptenoic acid, 7-[[[1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-(2-thienyl)ethyl]-2-thienyl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-55-9 CAPLUS


CN 5-Heptenoic acid, 7-[[[1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(2-(2-thienyl)ethyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291746-58-2 CAPLUS

CN 5-Heptenoic acid, 7-[[[1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-naphthalenylmethyl)-2-thienyl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-59-3 CAPLUS

CN 5-Heptenoic acid, 7-[[[1R,2R,3S,5S)-2-[[[5-(2-(2-methoxyphenyl)ethyl)-2-thienyl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-60-6 CAPLUS

CN 5-Heptenoic acid, 7-[[[1R,2R,3S,5S)-2-[[[5-(2-(2-hydroxyphenyl)ethyl)-2-thienyl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291746-56-0 CAPLUS

CN 5-Heptenoic acid, 7-[[[1R,2R,3S,5S)-2-[[[5-(2-(4-fluorophenyl)ethyl)-2-thienyl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-57-1 CAPLUS

CN 5-Heptenoic acid, 7-[[[1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(phenylmethyl)benzo[b]thien-2-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291746-61-7 CAPLUS

CN 5-Heptenoic acid, 7-[[[1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(3-thienylmethyl)-2-thienyl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-62-8 CAPLUS

CN 5-Heptenoic acid, 7-[[[1R,2R,3S,5S)-6,6-dimethyl-2-[[[6-(phenylmethyl)benzo[b]thien-2-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 291746-63-9 CAPLUS

CN 5-Heptenoic acid, 7-[[[1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(3-thienylmethyl)benzo[b]thien-2-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
Double bond geometry as shown.



RN 291746-64-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-thienylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-65-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(2-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-66-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(3-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-67-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[7-(3-thienylmethyl)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-68-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[4-(3-furanylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-69-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(1-naphthalenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-70-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(1-naphthalenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-71-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[7-(3-furanylmethyl)benzo[b]thien-3-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-72-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(9H-fluoren-2-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-73-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[(8-oxo-8H-indeno[2,1-b]thien-2-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-74-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[7-(3-thienylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-75-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[7-(phenylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-76-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[7-(4-methylphenyl)methyl]benzo[b]thien-2-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-77-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[7-(2-thienylmethyl)benzo[b]thien-2-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-78-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(1,1'-biphenyl)-2-ylmethyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-79-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[(9-oxo-9H-fluoren-3-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-80-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(4-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291746-81-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(benzo[b]thien-3-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291746-84-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-fluorophenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-85-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(4-(phenylmethoxy)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-86-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(4-(2-propenylmethoxy)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291746-82-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(4-hydroxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-83-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(9H-fluoren-3-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291746-87-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(1,3-benzodioxol-5-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-88-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-fluorophenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-89-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(3-(trifluoromethyl)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
 (CA INDEX NAME)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-90-2 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-chlorophenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291746-91-3 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,6-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-94-6 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dihydro-7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 291746-95-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(benzo[b]thien-6-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291746-92-4 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-trifluoromethylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-93-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(5-bromo-2,3-dihydro-7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-96-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(benzo[b]thien-5-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-97-9 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(benzo[b]thien-7-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291746-98-0 CAPLUS


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(5-hydroxybenzo[b]thien-3-yl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291746-99-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[[2-(hydroxymethyl)phenyl]methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-00-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(1-pyrrolidinylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-01-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[[2-[(dimethylamino)methyl]phenyl]methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-02-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[10,11-dihydro-5-oxo-5H-dibenzo[a,d]cyclohept-2-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291747-03-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(4-fluorophenyl)methyl]-2-furanyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-04-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(phenylmethyl)-2-furanyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-05-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(7-benzofuranyl)methyl]-2-


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-06-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[[2-[(methylphenylamino)methyl]phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-07-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(3-dibenzofuranyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291747-08-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dimethoxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-09-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(5-methyl-3-isoxazolyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291747-13-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[10,11-dihydro-5H-dibenzo[a,d]cyclohept-2-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-14-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2,3,4-trimethoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-15-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291747-10-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-methoxy-4-methylphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-11-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(5-methoxybenzo[b]thien-2-yl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-12-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(9H-fluoren-2-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-16-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(3,4,5-trimethoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-17-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(1,3-benzodioxol-4-ylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-18-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-(acetylamino)phenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-19-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-(methylsulfonyl)amino)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291747-22-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-methoxy-3-methylphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-23-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(4-(acetylamino)phenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-20-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(5-phenyl-2-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-21-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dihydro-1,4-benzodioxin-5-yl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291747-24-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(4-[(methylsulfonyl)amino]phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-25-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(4-dibenzothienyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-26-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(9H-fluoren-1-yl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-27-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-methoxy-3,4-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-28-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(4-dibenzofuranylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291747-31-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-methoxy-4,6-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-32-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-benzofuranylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-33-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(5-methoxy-3-benzofuranylmethyl)-2-thienyl]carbonyl]amino]-6,6-

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-29-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-ethylphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-30-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-methoxy-3,6-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291747-34-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(5-hydroxy-3-benzofuranylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-35-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(5-fluoro-3-benzofuranylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291747-36-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(5-methyl-3-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-37-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(6-methoxy-3-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-38-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(6-hydroxy-3-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-41-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(1,2-benzisoxazol-3-yl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-42-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(5-methoxy-1,2-benzisoxazol-3-yl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291747-39-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(6-fluoro-3-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-40-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(6-methyl-3-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291747-44-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(5-fluoro-1,2-benzisoxazol-3-yl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-45-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(5-methyl-1,2-benzisoxazol-3-yl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-46-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(5-chloro-4-phenyl)-2-thienyl]methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




IT 291747-47-2P 291747-48-3P 291747-49-4P
291747-50-7P 291747-51-8P 291747-52-9P
291747-53-0P 291747-54-1P 291747-55-2P
291747-56-3P 291747-57-4P 291747-58-5P
291747-59-6P 291747-60-9P 291747-61-0P
291747-62-1P 291747-63-2P 291747-64-3P
291747-65-4P 291747-66-5P 291747-67-6P
291747-68-7P 291747-69-8P 291747-70-1P
291747-71-2P 291747-72-3P 291747-73-4P
291747-74-5P 291747-75-6P 291747-76-7P
291747-77-8P 291747-78-9P 291747-79-0P
291747-80-3P 291747-81-4P 291747-82-5P
291747-83-6P 291747-84-7P 291747-85-8P
291747-86-9P 291747-87-0P 291747-88-1P
291747-89-2P 291747-90-5P 291747-91-6P
291747-92-7P 291749-94-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of [2.2.1] and [3.1.1]bicycloheptane as antagonists of PGD₂/TXA₂ receptors for treatment of asthma and nasal obstruction)

RN 291747-47-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(4-phenyl-2-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-48-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(4-(4-methoxyphenyl)-2-thienyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291747-49-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(4-(4-hydroxyphenyl)-2-thienyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-50-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(4-fluorophenyl)-2-thienyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291747-51-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(4-methylphenyl)-2-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291747-52-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(5-chloro-2-thienyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291747-53-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(5-phenyl-3-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 291747-54-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(4-phenyl-3-


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[5-(2-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-55-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-phenylmethyl)-3-thienyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-56-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-thiazolylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(7-isoquinolinylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-60-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(6-isoquinolinylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-61-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dihydro-4-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291747-57-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(2-benzothiazolylmethyl)-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-58-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(3-pyridinylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-59-6 CAPLUS

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291747-62-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dihydro-6-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-63-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dihydro-5-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-64-3 CAPLUS


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,4-difluorophenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-65-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,5-dimethyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-66-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(3-methyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(6-hydroxy-2-naphthalenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-70-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(6-hydroxy-2-naphthalenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-71-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(1-hydroxy-2-naphthalenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 291747-67-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-68-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-methyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 291747-69-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 291747-72-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(6-hydroxy-1-naphthalenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-73-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(4-(2-thienylmethyl)phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-74-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(1H-pyrrol-1-yl)sulfonyl]phenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-75-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-methyl-1H-pyrrol-1-yl)sulfonyl]phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-76-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dihydrothieno[3,2-b]furan-5-yl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-79-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(5-chloro-2,3-dihydro-7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-80-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dihydro-5-methyl-7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-77-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dihydrothieno[3,2-b]furan-6-yl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-78-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(5-fluoro-2,3-dihydro-7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-81-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dihydro-5-hydroxy-7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-82-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dihydro-4-phenyl-7-benzofuranyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-83-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dihydrothieno[3,4-b]furan-6-yl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-84-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2,3-dihydro-4-methylthieno[3,4-b]furan-6-yl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-87-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[7-(2-thienylmethyl)-3-benzofuranyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-88-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[7-(3-furanylmethyl)-3-benzofuranyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-85-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[7-(phenylmethyl)-3-benzofuranyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-86-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[7-(3-thienylmethyl)-3-benzofuranyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-89-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[7-(2-furanylmethyl)-3-benzofuranyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-90-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-methoxy-3,5-dimethylphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291747-91-6 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(2-furanylmethyl)-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 291747-92-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1S,2R,3R,4R)-3-[[[5-(3-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186532-85-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[4-(phenylthio)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271772-80-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1S,2R,3R,4R)-3-[[[1,1'-biphenyl]-4-ylcarbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 291749-94-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(5-phenyl-2-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




IT 186532-83-2P 186532-85-4P 271772-80-6P
 291744-49-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of [2.2.1] and [3.1.1]bicycloheptane as antagonists of PGD2/TA2 receptors for treatment of asthma and nasal obstruction)
 RN 186532-83-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[4-(phenylthio)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 291744-49-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-ylsulfonylethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:368150 CAPLUS
 DN 133:12765
 TI Preventives and/or remedies for central nervous system diseases containing compounds having TXA2 receptor antagonism and/or TXA2 synthase inhibitory effect
 IN Yagami, Tatsuhiro; Honma, Tsunetoshi; Katsura, Goro
 FA Shionogi & Co., Ltd., Japan
 SO PCT Int. Appl., 171 pp.
 CO:EN: PIXX02
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2000030683 A1 20000602 WO 1999-JP6317 19991112

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, HL, HR, HU, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI JP 1998-329862 A 19981119

OS MARPAT 133:12765

AB Comps. having TXA2 antagonism and/or a TXA2 synthase inhibitory effect, produgs thereof, pharmaceutically acceptable salts of the same or hydrates of the same, which show effects of inhibiting nerve cell denaturation caused by amyloid .beta. protein and nerve cell death caused by axonotmesis, are useful as preventives and/or remedies for central nervous system diseases, preventives and/or remedies for nerve degeneration diseases, nerve cell denaturation inhibitors, amyloid .beta. protein-induced nerve cell denaturation inhibitors, nerve cell death inhibitors, axonotmesis-induced nerve cell death inhibitors and, in particular, preventives and/or remedies for dementia of Alzheimer type.

IT 186532-83-2P 186532-85-4P 186532-87-6P
 271772-75-9P 271772-76-0P 271772-80-6P
 271772-82-8P 271772-88-4P 271772-90-8P
 271772-92-0P 271772-94-2P 271772-95-3P
 271772-96-4P 271772-97-5P 271772-98-6P
 271772-99-7P 271773-00-3P 271773-01-4P
 271773-02-5P 271773-03-6P 271773-04-7P
 271773-05-8P 271773-06-9P 271773-07-0P
 271773-08-1P 271773-09-2P 271773-10-5P
 271773-11-6P 271773-12-7P 271773-13-8P
 271773-14-9P 271773-15-0P 271773-16-1P
 271773-17-2P 271773-18-3P 271773-19-4P
 271773-20-7P 271773-21-8P 271773-22-9P
 271773-23-0P 271773-24-1P 271773-25-2P
 271773-26-3P 271773-27-4P 271773-28-5P
 271773-29-6P 271773-30-9P 271773-31-0P
 271773-32-2P 271773-34-3P 271773-35-4P
 271773-36-5P 271773-37-6P 271773-38-7P
 271773-39-8P 271773-40-1P 271773-41-2P

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


271773-42-3P 271773-43-4P 271773-44-5P
 271773-45-6P 271773-46-7P 271773-47-8P
 271773-48-9P 271773-49-0P 271773-50-3P
 271773-51-4P 271773-52-5P 271773-53-6P
 271773-54-7P 271773-55-8P 271773-56-9P
 271773-57-0P 271773-58-1P 271773-59-2P
 271773-60-3P 271773-61-4P 271773-62-7P
 271773-63-8P 271773-64-9P 271773-65-0P
 271773-66-1P 271773-67-2P 271773-69-4P
 271773-70-7P 271773-71-8P 271773-72-9P
 271773-73-0P 271773-74-1P 271773-75-2P
 271773-76-3P 271773-77-4P 271773-78-5P
 271773-79-6P 271773-80-9P 271773-81-0P
 271773-82-1P 271773-83-2P 271773-84-3P
 271773-85-4P 271773-86-5P 271773-87-6P
 271773-88-7P 271773-89-8P 271773-90-1P
 271773-91-2P 271773-92-3P 271773-93-4P
 271773-94-5P 271773-95-6P 271773-96-7P
 271773-97-8P 271773-98-9P 271773-99-0P
 271774-00-6P 271774-01-7P 271774-02-8P
 271774-03-9P 271774-04-0P 271774-05-1P
 271774-06-2P 271774-07-3P 271774-08-4P
 271774-09-5P 271774-10-6P 271774-11-7P
 271774-12-8P 271774-13-9P 271774-14-0P
 271774-15-1P 271774-16-2P 271774-17-3P
 271774-18-4P 271774-19-5P 271774-20-6P
 271774-21-7P 271774-22-8P 271774-23-9P
 271774-24-0P 271774-25-1P 271774-26-2P
 271774-27-3P 271774-28-4P 271774-29-5P
 271774-30-6P 271774-31-7P 271774-32-8P
 271774-33-9P 271774-34-0P 271774-35-1P
 271774-36-2P 271774-37-3P 271774-38-4P
 271774-39-5P 271774-40-6P 271774-41-7P
 271774-42-8P 271774-43-9P 271774-44-0P
 271774-45-1P 271774-46-2P 271774-47-3P
 271774-48-4P 271774-49-5P 271774-50-6P
 271774-51-7P 271774-52-8P 271774-53-9P
 271774-54-0P 271774-55-1P 271774-56-2P
 271774-57-3P 271774-58-4P 271774-59-5P
 271774-60-6P 271774-61-7P 271774-62-8P
 271774-63-9P 271774-64-0P 271774-65-1P
 271774-66-2P 271774-67-3P 271774-68-4P
 271774-69-5P 271774-70-6P 271774-71-7P
 271774-72-8P 271774-73-9P 271774-74-0P
 271774-75-1P 271774-76-2P 271774-77-3P
 271774-78-4P 271774-79-5P 271774-80-6P
 271774-81-7P 271774-82-8P 271774-83-9P
 271774-84-0P

RU: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preventives and/or remedies for central nervous system diseases contg. compds. having TXA2 receptor antagonism and/or TXA2 synthase inhibitory effect)

RN 186532-83-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[4-


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 (phenylthio)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 186532-85-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[4-(phenylthio)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 186532-87-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[4-(phenylthio)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, monosodium salt, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271772-75-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(1H-pyrrol-2-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 271772-76-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(1H-pyrrol-2-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 271772-80-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1S,2R,3R,4R)-3-[[[1,1'-biphenyl]-4-ylcarbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 271772-82-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1S,2R,3R,4R)-3-[[[1,1'-biphenyl]-4-ylcarbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 271772-88-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(3-hydroxyphenyl)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271772-95-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(phenylamino)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271772-96-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(phenylsulfonyl)amino]-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271772-90-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(4-methoxyphenyl)thio]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271772-92-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[3-[(4-methoxyphenyl)thio]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271772-94-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(1H-pyrrol-1-




L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271772-97-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(benzoylamino)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271772-98-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271772-99-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylmethyl)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-00-3 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(phenylsulfonyl)amino]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-01-4 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-[(phenylamino)sulfonyl]-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-04-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(3-methyl-1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-05-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[3-(1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-02-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-[(1H-pyrrol-1-yl)sulfonyl]-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-03-6 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-[(1H-pyrrol-1-yl)sulfonyl]-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-06-9 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(2-methyl-1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-07-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-08-1 CAPLUS


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(1H-indol-1-ylsulfonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-09-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(2-(hydroxymethyl)-1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-10-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(2-thiazolylamino)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-13-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(2-thienylthio)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-14-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(2-thienylsulfonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-15-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(2-pyridinylamino)carbonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-11-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(2-thiazolylamino)carbonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-12-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(3-thienylthio)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-16-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(3-thienylthio)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-17-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(3-thienylsulfonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-18-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-yl)-2-furanyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-19-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-23-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-24-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylthio)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-25-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271773-20-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylamino)sulfonyl]benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-21-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-ylsulfonyl]benzo[b]thien-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-22-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1H-pyrrol-1-ylsulfonyl)-2-furanyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-26-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(benzoylamino)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-27-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-28-5 CAPLUS


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[(5-phenyl-2-thienyl)carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-29-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[(5-benzoyl-2-thienyl)carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-30-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[(2,3'-bithiophen)-5-ylcarbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-35-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-(2-thienylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-36-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-(2-thienylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-37-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-(1H-imidazol-1-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-31-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-(4-methylphenyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-33-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-34-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-(2-thienylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-38-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-(1H-pyrazol-1-ylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-39-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-(phenylsulfonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271773-40-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-[(4-methoxyphenyl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-41-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-(2-thienylcarbonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-42-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-(1H-pyrrol-1-ylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-45-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-(benzoylamino)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-46-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-47-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-methyl-5-(1H-pyrrol-1-ylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-43-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-(1H-pyrrol-1-yl)-4-(1H-pyrrol-1-ylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-44-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-(2-methyl-1H-pyrrol-1-ylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-48-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[5-(2-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-49-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-(phenylthio)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-50-3 CAPLUS


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-phenoxy-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-51-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[6-(1H-pyrrol-1-yl)sulfonyl]benzo[b]thien-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-52-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[2-(benzoylamino)-4-methyl-5-thiazolyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-55-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(2-thienylmethyl)thio]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-56-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(2-thienylmethyl)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-57-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-thienylamino)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271773-53-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-methyl-2-[(phenylsulfonyl)amino]-5-thiazolyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-54-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[3-methyl-6-phenylimidazo[2,1-b]thiazol-2-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-58-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(3-thienylamino)sulfonyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-59-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(phenylamino)carbonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271773-60-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-fluorophenyl)amino]carbonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271773-61-6 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(4-methoxyphenyl)amino]carbonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271773-62-7 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3,4,5-trimethoxyphenyl)amino]carbonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271773-65-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(2-thienylsulfonyl)methyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 271773-66-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-thienylamino)carbonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271773-67-2 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-(hydroxymethyl)-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-63-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(1H-pyrrol-1-yl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271773-64-9 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-[(2-thienylthio)methyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-69-4 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271773-70-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-thienylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271773-71-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methyl-2-thienyl)thio]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
Double bond geometry as shown.




RN 271773-72-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(5-methyl-2-thienyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-73-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[2-(2-thienylthio)-4-thiazolyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-74-1 CAPLUS

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-77-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(3-thienylmethyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-78-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(3-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-79-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1-(phenylmethyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(phenylmethyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-75-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(2-thienylmethyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-76-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[4-(4-fluorophenyl)methyl]benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
Double bond geometry as shown.




RN 271773-80-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1-(2-thienylmethyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-81-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1-(3-thienylmethyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-82-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1-(phenylsulfonyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-83-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylmethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-84-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[1-(2-thienylsulfonyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-85-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[2-(1H-pyrrol-1-yl)-4-thiazolyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271773-88-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1E)-2-(3-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271773-89-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1Z)-2-(3-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-90-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(5-methyl-3-thienyl)thio]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-86-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylthio)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-87-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylsulfonyl)-3-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-91-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(5-methyl-3-thienyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-92-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1Z)-2-(2-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271773-93-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(1E)-2-(2-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-94-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-thienylthio)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271773-95-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-thienylsulfonyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271773-99-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(2-thienylcarbonyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-00-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(methoxyimino)-2-thienylmethyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.




RN 271774-01-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(phenylamino)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271773-96-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-thienylmethyl)thio]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271773-97-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-thienylsulfinyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 271773-98-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(5-methyl-2-thienyl)sulfinyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-02-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-(methylphenylamino)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-03-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-methylphenyl)thio]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-04-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-methylphenyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)-(9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-05-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-methoxyphenyl)thio]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-06-2 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-methoxyphenyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271774-09-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-10-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-hydroxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-11-9 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-acetoxymethyl)phenyl]methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-07-3 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-hydroxyphenyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-08-4 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(3-hydroxyphenyl)thio]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-13-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(phenylthio)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-14-2 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(phenoxymethyl)-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-15-3 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(phenylamino)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-16-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-17-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[[5-[(2-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(phenylmethyl)-3-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-21-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(1H-pyrrol-1-yl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-22-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-[(phenylamino)sulfonyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-18-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(phenylsulfonyl)amino]-3-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-19-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(benzoylamino)-3-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-20-0 CAPLUS

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271774-23-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-[(phenylsulfonyl)amino]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-24-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271774-25-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[2-phenylbenzo[b]thien-5-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-26-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[3-(1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-29-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[4-(1H-indol-1-yl)sulfonyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-30-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(1H-pyrrol-1-yl)sulfonyl]-3-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-31-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271774-27-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(2-methyl-1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-28-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-32-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[4-[[2-(hydroxymethyl)-1H-pyrrol-1-yl)sulfonyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-33-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[4-(1H-pyrrol-1-yl)sulfonyl]-3-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271774-34-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-thienylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-35-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[1-(2-thienylsulfonyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-((5-methyl-2-thienyl)thio)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-39-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-((5-methyl-2-thienyl)thio)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-40-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[1-[(4-fluorophenyl)sulfonyl]-1H-pyrrol-3-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-36-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[1-(phenylsulfonyl)-1H-pyrrol-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-37-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-thienylthio)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-38-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-((5-methyl-2-

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271774-41-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[1-[(4-methoxyphenyl)sulfonyl]-1H-pyrrol-3-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-42-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-thienyl)-1H-pyrrol-2-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-43-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-((1E)-2-(3-thienyl)ethenyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-44-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(1E)-2-(3-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-45-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(5-methyl-3-thienyl)thio]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-46-0 CAPLUS

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-49-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(1E)-2-(2-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-50-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-methyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-52-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-thienyl)sulfinyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(5-methyl-3-thienyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-47-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(phenylmethyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 271774-48-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-thienyl)ethenyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 271774-53-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(5-methyl-2-thienyl)sulfinyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 271774-54-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-55-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(2-hydroxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-56-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(2-(acetyloxy)phenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-57-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(phenylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271774-60-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-methoxyphenyl)thio]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-61-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-methoxyphenyl)sulfonyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-62-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-hydroxyphenyl)sulfonyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-58-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(3-methylphenyl)thio]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-59-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(3-methylphenyl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 271774-63-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-hydroxyphenyl)thio]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-64-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-[(3-methoxyphenyl)methyl]-2-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-65-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(methylphenylamino)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI)
(CA INDEX NAME)

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-66-4 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-methylphenyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-67-5 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-(2-thienyl)methyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 271774-71-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1S,2S,3R,5R)-6,6-dimethyl-3-[[[5-(2-methyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-72-2 CAPLUS

CN 5-Heptenoic acid, 7-[(1S,2S,3R,5R)-6,6-dimethyl-3-[[[5-(2-thienylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.

RN 271774-73-3 CAPLUS

CN 5-Heptenoic acid, 7-[(1S,2S,3R,5R)-6,6-dimethyl-3-[[[5-(1H-pyrrol-1-ylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 271774-68-6 CAPLUS

CN 5-Heptenoic acid, 7-[(1S,2S,3S,5R)-6,6-dimethyl-3-[[[5-(1H-pyrrol-1-ylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-69-7 CAPLUS

CN 5-Heptenoic acid, 7-[(1S,2S,3S,5R)-6,6-dimethyl-3-[[[5-(3-thienylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-70-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1S,2S,3S,5R)-6,6-dimethyl-3-[[[5-(2-thienylsulfonyl)-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Double bond geometry as shown.



RN 271774-74-4 CAPLUS

CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(1H-pyrrol-1-ylsulfonyl)-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

RN 271774-75-5 CAPLUS

CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(2-thienylsulfonyl)-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271774-76-6 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(3-thienylsulfonyl)-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-77-7 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-[(2-methyl-1H-pyrrol-1-yl)sulfonyl]-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271774-80-2 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[4-(4-methoxyphenoxy)benzoyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-81-3 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-[(2-thienylthio)methyl]-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271774-78-8 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(phenylmethyl)-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-79-9 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(phenyl-3-thienyl)carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 271774-82-4 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-(phenoxymethyl)-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 271774-83-5 CAPLUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-[(phenylamino)methyl]-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 7 OF 17 CAPIUS COPYRIGHT 2003 ACS (Continued)



RN 271774-84-6 CAPIUS
 CN 5-Hexenoic acid, 6-[(1S,2S,3R,4R)-3-[[[5-[(phenylthio)methyl]-2-thienyl]carbonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 8 OF 17 CAPIUS COPYRIGHT 2003 ACS
 AN 1999:783967 CAPIUS
 DN 132:26854
 TI Anti-itching agents containing PGD2 antagonists
 IN Arimura, Akinori
 PA Shionogi & Co., Ltd., Japan
 SO PCT Int. Appl., 51 pp.
 CODEN: PIXX02
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9962555	A1	19991209	WO 1999-JP2820	19990528
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 233868	AA	19991209	CA 1999-233868	19990528
AU 9939551	A1	19991220	AU 1999-39551	19990528
EP 1084711	A1	20010321	EP 1999-922538	19990528
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
US 2002058693	A1	20020516	US 2001-881799	20010618
US 6506789	B2	20030114		
PRAI JP 1998-154332	A	19980603		
WO 1999-JP2820	W	19990528		
US 2000-700283	A1	20001113		


OS MARPAT 132:26854
 AB Disclosed are PGD2 antagonists, e.g., (5Z)-7-[(1R,2R,3S,5S)-2-(5-hydroxybenzo[b]thiophene-3-yl-carbonylamino)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoic acid (I), and pharmaceutically acceptable salts thereof or hydrates of the same which have an excellent effect of preventing or treating itching and therefore are useful as drugs. The PGD2 antagonist I showed inhibitory effect on scratching behavior of C57BL mice stimulated by compd. 48/80 or antigen. Also, a tablet contg. 140, hydroxypropylcellulose 3.6, Mg stearate 0.4, corn starch 18, and lactose 58 mg was prepd.
 IT 209268-36-OP

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (anti-itching agents contg. PGD2 antagonists)

RN 209268-36-0 CAPIUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 8 OF 17 CAPIUS COPYRIGHT 2003 ACS (Continued)



IT 186533-72-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (anti-itching agents contg. PGD2 antagonists)

RN 186533-72-2 CAPIUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




IT 209268-47-3 209268-52-0 209268-54-2
 209268-55-3 209268-56-4 251957-50-3
 251957-51-4 251957-52-5 251957-53-6
 251957-55-8
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); USES (Uses)
 (anti-itching agents contg. PGD2 antagonists)

RN 209268-47-3 CAPIUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(5-bromobenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 8 OF 17 CAPIUS COPYRIGHT 2003 ACS (Continued)




RN 209268-52-0 CAPIUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 209268-54-2 CAPIUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(5-acetyloxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 209268-55-3 CAPIUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


L8 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 209268-56-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(5-hydroxybenzo[b]thien-3-yl)carbonylamino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 251957-50-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(6-hydroxybenzo[b]thien-3-yl)carbonylamino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, monosodium salt, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L8 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



● Na

RN 251957-53-6 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(benzo[b]thien-3-ylcarbonylamino)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, monosodium salt, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




● Na

RN 251957-55-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1S,2R,3S,5R)-2-[(5-fluorobenzo[b]thien-3-yl)carbonylamino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L8 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



● Na

RN 251957-51-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(5-fluorobenzo[b]thien-3-yl)carbonylamino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 251957-52-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(5-fluorobenzo[b]thien-3-yl)carbonylamino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, monosodium salt, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L8 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 209268-37-1P 209268-43-9P 209268-44-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anti-itching agents contg. PGD2 antagonists)
RN 209268-37-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(5-hydroxybenzo[b]thien-3-yl)carbonylamino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, monosodium salt, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



● Na


RN 209268-43-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3R,5S)-2-[(5-hydroxybenzo[b]thien-3-yl)carbonylamino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 209268-44-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



IT 209268-42-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of PGD2 antagonists as anti-itching agents)
 RN 209268-42-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3R,5S)-2-[[[5-(phenylsulfonyl)oxy]benzo[b]thien-3-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

1999:640851 CAPLUS

DN 131:243177

TI Process for producing benzothiophenecarboxylic acid amide derivatives
 IN Honma, Tsunetoshi; Hiramatsu, Yoshiharu; Okada, Tetsuo; Kakinuma, Makoto
 PA Shionogi & Co., Ltd., Japan
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXKD2
 DT Patent
 LA Japanese
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9950261	A1	19991007	WO 1999-JP1617	19990330
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZV, AM, AZ, BY, KG, KZ, MD, RU, TJ, TW			
RW:	GH, GW, KE, LS, MW, SD, SL, SZ, UG, ZV, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2326418	AA	19991007	CA 1999-2326418	19990330
AU 9929602	A1	19991018	AU 1999-29602	19990330
AU 747860	B2	20020523		
BR 9909286	A	20001205	BR 1999-9286	19990330
EP 1069123	A1	20010117	EP 1999-910765	19990330
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
TW 458975	B	20011011	TW 1999-88105051	19990330
JP 2002193898	A2	20020710	JP 2001-353060	19990330
RU 2185380	C1	20020720	RU 2000-2000127103	19990330
JP 3340428	B2	20021105	JP 2000-541165	19990330
NO 200004918	A	20001128	NO 2000-4918	20000929
US 6399788	B1	20020604	US 2000-647353	20000929
US 2002115871	A1	20020822	US 2002-133353	20020429
US 6462241	B2	20021008		
US 6455741	B1	20020924	US 2002-133319	20020429
US 2002156297	A1	20021024		
US 6465662	B1	20021015	US 2002-133313	20020429
US 2002161242	A1	20021031		
PRAI JP 1998-87311	A	19980331		
JP 2000-541165	A3	19990330		
WO 1999-JP1617	B	19990330		
US 2000-647353	A3	20000929		
OS CASREACT 131:243177; MARPAT 131:243177				
GI				




IT 209268-35-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of PGD2 antagonists as anti-itching agents)
 RN 209268-35-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[5-(acetyloxy)benzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB Disclosed are a process for producing 7-[(1R,2R,3S,5S)-2-((hydroxybenzo[b]thiophen-3-ylcarbonyl)amino)-10-norpinan-3-yl]-5-heptenoic acid compds. having PGD2 antagonism represented by formula (I); R = H, HO-protecting group; X = H, alkyl; the double bond is either in E or Z configuration), pharmaceutically acceptable salts thereof or hydrates of the same characterized by reacting an amino alc., namely [(1R,2R,3R,5S)-2-amino-10-norpinan-3-yl]ethanol, of formula (II) or its salt with a hydroxybenzo[b]thiophene-3-carboxylic acid compd. of formula (III) or its reactive deriv., oxidizing the obtained product in the presence of 2,2,6,6-tetramethylpiperidine-1-oxyls, and then reacting with an ylide under Wittig reaction conditions optionally followed by deblocking. The amino alc. (II) is prepd. by redn. of oximes (IV); R2 = alkyl; R3 = H, alkyl). I are useful for the treatment of diseases related to failure of mast cell function caused by over-prodn. of PGD and are used as remedies for systemic mast cell disease or mast cell activation disorder, allergic rhinitis, allergic conjunctivitis, nettle rash (urticaria), ischemic reperfusion disorder, and atopic dermatitis and as bronchodilators, antiasthmatics, and antiinflammatory agents (no data). II.PhCO2H (prepn. given) was suspended in water, treated with 1 N aq. HCl, and extd. with EtOAc to remove pptd. benzoic acid. The org. layer was washed with water and the combined aq. layer was treated with 4 N aq. NaOH under ice-cooling and then dropwise with a soln. of 5-(benzenesulfonyloxy)benzo[b]thiophene-3-carbonyl chloride in THF over 15 min and stirred at the same temp. for 15 h to give 95.6% intermediate (V; R1 = CH2OH). The latter alc. was dissolved in EtOAc, treated with TEMPO and KBr and then dropwise with a soln. of 0.41 N aq. NaOCl (adjusted to pH 9.5 with NaHCO3) at -1.degree. to 6.degree. over 3 min, and stirred at the same temp. for 10 min to give 100% aldehyde (V; R1 = CHO) which underwent Wittig reaction with 4-carboxybutyltriphenylphosphonium bromide in the


L8 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 presence of Me3COX in THF under ice-cooling for 2 h followed by treatment with a mixt. of 4 N aq. NaOH and DMSO at 55.degree. for 2 h to give II 76.0% (OR = 5-OH, X = H).
 IT 244246-69-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of [(5-hydroxybenzo[b]thiophenylcarbonylamino)norpnan-3-yl]-5-heptenoic acid derivs. as PGD2 antagonists for therapeutics)
 RN 244246-69-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[(5-phenylsulfonyloxy)benzo[b]thien-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



IT 209268-36-0P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of [(5-hydroxybenzo[b]thiophenylcarbonylamino)norpnan-3-yl]-5-heptenoic acid derivs. as PGD2 antagonists for therapeutics)
 RN 209268-36-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




ANSWER 10 OF 17 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:640850 CAPLUS
 DN 131:243176
 TI Process for producing 5-hydroxybenzo[b]thiophene-3-carboxylic acid derivatives
 IN Honma, Tsunetoshi; Hiramatsu, Yoshiharu
 PA Shionogi & Co., Ltd., Japan
 SO PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9950260	A1	19991007	WO 1999-JP1616	19990330
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZV, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2326419	AA	19991007	CA 1999-2326419	19990330
AU 9929601	A1	19991018	AU 1999-29601	19990330
AU 745129	B2	20020314		
BR 9909290	A	20001205	BR 1999-9290	19990330
EP 1069122	A1	20010117	EP 1999-910764	19990330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002167383	A2	20020611	JP 2001-353051	19990330
RU 2186065	C1	20020727	RU 2000-200012710819990330	
NO 2000004919	A	20001128	NO 2000-4919	20000929
US 6320060	B1	20011120	US 2000-647354	20000929
US 2002016476	A1	20020207	US 2001-962189	20010926
US 6346629	B2	20020212		
US 2002026061	A1	20020228	US 2001-962439	20010926
US 6495702	B2	20021217		
PRAI JP 1998-95819	A	19980331		
JP 2000-541164	A3	19990330		
WO 1999-JP1616	W	19990330		
US 2000-647354	A3	20000929		
CASREACT 131:243176; MARPAT 131:243176				
GI				

L8 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




AB Disclosed are a process for producing benzothiophenic acid derivs. (I; R = H, HO-protecting group) which are useful as starting materials for producing drugs and a process for producing 7-[(1R,2R,3S,5S)-2-[(5-hydroxybenzo[b]thiophen-3-ylcarbonylamino)-10-norpnan-3-yl]-5-heptenoic acid derivs. (II; R = H, HO-protecting group; X = H, alkyl) the double bond is either in E or Z configuration), which are specific PGD2 antagonists, by using the above derivs. (I). II are useful for the treatment of diseases related to failure of mast cell function caused by over-prodn. of PGD2 and are used as remedies for systemic mast cell disease or mast cell activation disorder, allergic rhinitis, allergic conjunctivitis, nettle rash (urticaria), ischemic reperfusion disorder, and atopic dermatitis and as bronchodilators, antispasmodics, and antiinflammatory agents (no data). Thus, 4-mercaptophenol was alkylated by propargyl bromide in the presence of Et3N in EtOAc under ice-cooling for .apprx.2 h and then sulfonated by benzenesulfonyl chloride in the presence of Et3N under ice-cooling for .apprx.1.5 h and at room temp. for 30 min to give 100% crude 4-(propargylthio)phenyl benzenesulfonate. The latter compd. was oxidized by 31% aq. H2O2 and formic acid in MeOH for 3.5 h to give 100% crude 4-(propargylsulfinyl)phenyl benzenesulfonate which was dissolved in 1,2-dimethoxyethane and refluxed for 4 h, treated with water and p-MeC6H4SO3H.H2O, and refluxed for 2 h to give 100% crude 5-benzenesulfonyloxy-3-hydroxymethylbenzo[b]thiophene. The latter compd. was oxidized by TEMPO and an aq. soln. of 0.81 N NaOCl (adjusted to pH 8.6 by adding 1 N H2SO4) at -1.degree. to 8.degree. for 40 min and then with 1 N aq. NaOCl and 31% aq. H2O2 at room temp. for 2 h to give 51.7% 5-(benzenesulfonyloxy)benzo[b]thiophene-3-carboxylic acid (I; R = benzenesulfonyl) which was refluxed with SOCl2 in the presence of one drop of DMF for 1.5 h to give 5-(benzenesulfonyloxy)benzo[b]thiophene-3-carboxylic acid chloride. This compd. was condensed with 2-[(1R,2R,3S,5S)-2-amino-10-norpnan-3-yl]ethanol in aq. THF contg. NaOH under ice-cooling for 1 h to give 95.6% intermediate (III; R1 = CH2OH) which was oxidized by oxalyl chloride/DMSO in dimethoxyethane at -55.degree. to -60.degree. for 30 min to give 100% aldehyde (III; R1 = CHO) and underwent Wittig reaction with 4-carboxybutyltriphenylphosphonium bromide in the presence of Me3COX in THF under ice-cooling for 2 h followed by treatment with a mixt. of 4 N aq. NaOH and DMSO at 55.degree. for 2 h to give II 76.0% (R = X = H).

L8 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


IT 244246-69-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of hydroxybenzo[b]thiophenecarboxylic acid derivs. and [(hydroxybenzo[b]thiophenylcarbonylamino)norpinanyl]heptenoic acid derivs. as PGD2 antagonists for therapeutics)
 RN 244246-69-3 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-6,6-dimethyl-2-[[[5-[(phenylsulfonyl)oxy]benzo[b]thien-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



IT 209268-36-0P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of hydroxybenzo[b]thiophenecarboxylic acid derivs. and [(hydroxybenzo[b]thiophenylcarbonylamino)norpinanyl]heptenoic acid derivs. as PGD2 antagonists for therapeutics)
 RN 209268-36-0 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-2-[[[5-(hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD

L8 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS

AN 1999:402435 CAPLUS
 DN 129:81869
 TI preparation of benzothienothiophenecarboxamide derivatives as PGD2 antagonists
 IN Honma, Tsunetoshi; Hiramatsu, Yoshiharu; Arimura, Akinori
 PA Shionogi & Co., Ltd., Japan; Honma, Tsunetoshi; Hiramatsu, Yoshiharu; Arimura, Akinori
 SO PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9825919	A1	19980618	WO 1997-JP4527	19971210
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BU, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9711039	A	19980615	ZA 1997-11039	19971209
AU 9854097	A1	19980703	AU 1998-54097	19971210
AU 718958	B2	20000504		
EP 944614	A1	19990929	EP 1997-947866	19971210
EP 944614	B1	20020311		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1240438	A	20000105	CN 1997-180628	19971210
BR 9714016	A	20000229	BR 1997-14016	19971210
JP 2000514824	T2	20001107	JP 1998-526492	19971210
JP 3215441	B2	20011009		
RU 2151617	C1	20010110	RU 1999-115766	19971210
IL 130660	A1	20020310	IL 1997-130660	19971210
AT 223911	E	20020915	AT 1997-947866	19971210
TW 438790	B	20010607	TW 1997-86118667	19971211
US 6083974	A	20000704	US 1999-308176	19990517
NO 9902838	A	19990720	NO 1999-2838	19990610
MX 9905469	A	20000228	MX 1999-5469	19990611
PRAI JP 1996-333495	A	19961213		
JP 1997-254001	A	19970919		
WO 1997-JP4527	W	19971210		
OS MARPAT 129:81869				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I and II (R = H, alkyl, alkoxy, halo, hydroxy, acyloxy. (Un)substituted arylsulfonyloxy; X = H, alkyl; the chain double bond may be E or Z) and their pharmaceutically acceptable salts were prepd. as agents having PGD2-antagonistic activities, inhibitory activities against infiltration of eosinophils, and being useful as a drug for treating diseases, such as systemic mastocytosis and disorder of systemic mast cell activation, as well as tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, ischemic reperfusion injury.


L8 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 inflammation and atopic dermatitis. Thus, the bicycloheptyl heptenoate III was treated with 5-acetoxybenzo[b]thiophene-3-carbonyl chloride followed by hydrolysis to give the benzo[b]thiophenylcarbonylamino bicycloheptylheptenoate IV (R = H, Na). The binding IC50 of IV (R = H) with PGD2 receptor was 0.4 nM.


IT 209268-35-9P 209268-36-0P 209268-42-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of benzothienothiophenecarboxamide derivs. as PGD2 antagonists)
 RN 209268-35-9 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-2-[[[5-(acetoxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 209268-36-0 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2R,3S,5S)-2-[[[5-(hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 209268-42-8 CAPLUS
 CN 5-Heptenoic acid, 7-[[[(1R,2S,3R,5S)-6,6-dimethyl-2-[[[5-[(phenylsulfonyl)oxy]benzo[b]thien-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.
Double bond geometry as shown.



IT 209268-37-1P 209268-43-9P 209268-44-0P

209268-46-2P 209268-47-3P 209268-50-8P

209268-51-9P 209268-52-0P 209268-53-1P

209268-54-2P 209268-55-3P 209268-56-4P

209268-58-6P 209268-59-7P 209268-60-0P

209268-62-2P 209268-63-3P 209268-64-4P

209268-66-6P 209272-21-9P


RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of benzothienophenecarboxamide derivs. as PGD2 antagonists)

RN 209268-37-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




• Na

RN 209268-43-9 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3R,5S)-2-[[[(5-hydroxybenzo[b]thien-3-


L8 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 209268-47-3 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[(5-bromobenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 209268-50-8 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[(6-bromobenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 209268-51-9 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[(7-bromobenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 209268-44-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 209268-46-2 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[(4-bromobenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L8 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 209268-52-0 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[(6-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 209268-53-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[(7-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L8 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 209268-54-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[(5-(acetyloxy)benzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 209268-55-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[[[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 209268-59-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1S,2R,3R,5R)-3-[(benzo[b]thien-3-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 209268-60-0 CAPLUS
 CN 5-Heptenoic acid, 7-[(1S,2R,3R,5R)-3-[[[(5-fluorobenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 209268-62-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1S,2R,3R,5R)-3-[[[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 209268-56-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[[[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 209268-58-6 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2S,3S,5S)-2-[[[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L8 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 209268-63-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1S,2S,3S,5R)-3-[(benzo[b]thien-3-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 209268-64-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1S,2S,3S,5R)-3-[[[(5-fluorobenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 209268-66-6 CAPLUS

09/936,161


L8 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1S,2S,3S,5R)-3-[[[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 209272-21-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1S,2S,3S,5R)-2-[[[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



IT 209268-45-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of benzothiophenecarboxamide derivs. as PGD2 antagonists)
 RN 209268-45-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5E)-, compd. with 4-methoxybenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 209268-44-0
 CMF C25 H31 N O4 S

L8 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2003 ACS
 CN 1998:402431 CAPLUS
 DN 129:67691
 TI Preparation of fused heterocyclic benzenecarboxylic acid amide derivatives
 IN PGD2 antagonists
 IN Honma, Tsunetoshi; Hiramatsu, Yoshiharu; Arimura, Akinori
 PA Shionogi & Co., Ltd., Japan; Honma, Tsunetoshi; Hiramatsu, Yoshiharu; Arimura, Akinori
 SO PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9825915	A1	19980618	WO 1997-JP4526	19971210
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9854096	A1	19980703	AU 1998-54096	19971210
EP 945450	A1	19990929	EP 1997-947865	19971210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6069166	A	20000530	US 1999-319022	19990528
JP 1996-331962		19961212		
WO 1997-JP4526		19971210		
OS MARPAT 129:67691				
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I: R1-R5 = H, alkyl, alkoxy, alkylthio, halo, etc.; Y = O, S; X = H, alkyl] are prepd. I have PGD2 antagonism and inhibitory effects on eosinophilic infiltration and are useful as remedies for diseases in which mast cell dysfunction participates, systemic mastocytosis and systemic mast cell activation disorders, tracheal constriction inhibitors, anti-asthmatic agents, anti-allergic rhinitis drugs, anti-allergic conjunctivitis drugs, anti-urticarial drugs, remedies for ischemic reflow disorders, anti-inflammatory agents, and anti-atopic dermatitis agents. Thus, compd. (II: W = H, X = Me) was reacted with benzo[b]thiophene-7-carbonyl chloride in the presence of Et3N to give the title compd. II [W = benzo[b]thiophene-7-carbonyl, X = H], which showed IC50 of 42 nM against PGD2 receptor when tested with human platelet rich plasma.

IT 197069-43-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of fused heterocyclic benzenecarboxylic acid amide derivs. as PGD2 antagonists)
 RN 197069-43-5 CAPLUS


Page 127

L8 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



CM 2


CRN 2393-23-9
 CMF C8 H11 N O



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(benzo[b]thien-7-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



IT 209001-72-9P 209001-78-5P 209001-80-9P
 209001-84-3P 209001-86-5P 209001-88-7P
 209001-90-1P 209001-91-2P 209001-92-3P
 209001-93-4P 209001-94-5P 209001-96-7P
 209001-97-8P 209001-98-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of fused heterocyclic benzenecarboxylic acid amide derivs. as PGD2 antagonists)
 RN 209001-72-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(benzo[b]thien-7-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 209001-78-5 CAPLUS


L8 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(benzo[b]thien-7-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, monosodium salt, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 209001-80-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(2,3-dibromobenzo[b]thien-7-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 209001-84-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[(3-methylbenzo[b]thien-7-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

L8 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 209001-90-1 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(3-bromobenzo[b]thien-7-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 209001-91-2 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(2-bromobenzo[b]thien-7-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L8 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 7-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 209001-86-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[(2-methylbenzo[b]thien-7-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 209001-88-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[(2-methylthio)benzo[b]thien-7-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L8 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 209001-92-3 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(3-(1,1-dimethylethyl)benzo[b]thien-7-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 209001-93-4 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[(4-dibenzothienylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 209001-94-5 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-6,6-dimethyl-2-[(naphtho[2,1-b]thien-4-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 209001-96-7 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[6-methoxynaphtho[2,1-b]thien-4-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 209001-97-8 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[4-(dimethylaminocarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 209001-98-9 CAPLUS
 CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[[3-methoxybenzo[b]thien-7-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

~~L8~~ ANSWER 13 OF 17 CAPLUS COPYRIGHT 2003 ACS
 1997:638467 CAPLUS

~~DI~~ 127:287701

~~TI~~ Bicyclo[2.2.1]heptane and 6,6-Dimethylbicyclo[3.1.1]heptane Derivatives: Orally Active, Potent, and Selective Prostaglandin D2 Receptor Antagonists

~~AU~~ Tsuchi, Tatsuo; Honma, Tsunetoshi; Hiramatsu, Yoshiharu; Okada, Toshihiko; Hashizume, Hiroshi; Mitsumori, Susumu; Inagaki, Masanao; Arimura, Akinori;

~~Yasui, Kiyoshi; Asanuma, Fujio; Kishino, Junji; Ohtani, Mitsuaki~~

~~CS~~ Shionogi Research Laboratories, Shionogi Co., Osaka, 553, Japan

~~SO~~ Journal of Medicinal Chemistry (1997), 40(22), 3504-3507

~~CODEN: JMCMAR~~ ISSN: 0022-2623

~~PB~~ American Chemical Society

~~DT~~ Journal

~~LA~~ English

~~AB~~ Novel prostaglandin D2 (PGD2) receptor antagonists were synthesized as a potential new class of anti-allergic agents having two series of bicyclo[2.2.1]heptane and 6,6-dimethylbicyclo[3.1.1]heptane ring systems with sulfonylamino or carbonylamino groups. Some of them exhibited extremely potent antagonism of the PGD2 receptor in radioligand binding and cAMP formation assays with IC50s below 1 nM, and much less antagonism of thromboxane A2 (TXA2) and prostaglandin I2 (PGI2) receptors. These potent PGD2 receptor antagonists, when administered orally, dramatically suppressed various allergic inflammatory responses such as increased vascular permeability and eosinophil infiltration in allergic rhinitis, conjunctivitis and asthma models. These excellent pharmacol. profiles of PGD2 receptor antagonists, originally synthesized in our labs., are of potentially great clinical significance. This study also provides the first exptl. evidence suggesting that PGD2 plays an important role in the pathogenesis of allergic diseases.

~~IT~~ 186531-17-9P 186531-64-6P 186531-87-3P

~~186532-67-2P 197069-38-8P 197069-39-9P~~

~~197069-40-2P 197069-41-3P 197069-42-4P~~

~~197069-43-5P 197069-44-6P~~

~~RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)~~


~~(prepn. and structure of bicycloheptane derivs. as orally active, potent, and selective PGD2 antagonists)~~

~~RN 186531-17-9 CAPLUS~~

~~CN 5-Heptenoic acid, 7-[3-[[[4-(phenylazo)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, [15-[(1.alpha.,2.alpha.(Z),3.beta.,4.alpha.)]- (9CI) (CA INDEX NAME)~~

~~Absolute stereochemistry.~~

~~Double bond geometry as described by E or Z.~~




RN 186531-64-6 CAPLUS

CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[[4-(phenylazo)benzoyl]amino]bicyclo[3


L8 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 .1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.



RN 186531-87-3 CAPLUS
 CN 5-Heptenoic acid, 7-[2-(benzoylamino)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-67-2 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[(3-thienylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 197069-38-8 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(1H-pyrrol-2-ylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 197069-39-9 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[(benzo[b]thien-3-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 197069-40-2 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[(5-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 197069-41-3 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[(5-fluorobenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 197069-42-4 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[(6-hydroxybenzo[b]thien-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 197069-43-5 CAPLUS
 CN 5-Heptenoic acid, 7-[[[1R,2R,3S,5S]-2-[(benzo[b]thien-7-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 197069-44-6 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[(2-dibenzofuran-2-yl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 are in the form of rings, they may be optionally substituted] or salts thereof or hydrates thereof are prepd. These compds. are useful as a PGD2 antagonists and thus usable in, for example, a remedy for systemic mastocytosis or systemic mast cell activation disorders, a drug for bronchoconstriction, an antiasthmatic, a drug for allergic rhinitis agent, a drug for allergic conjunctivitis, a drug for urticaria, a remedy for ischemia reperfusion disorders or an antiinflammatory agent. They are particularly useful in the treatment of nasal occlusion. Thus, a bicyclo[2.2.1]heptane deriv. (II; R = Me, R' = H) was condensed with 2-chlorosulfonyldibenzofuran in the presence of Et3N in CH2Cl2 to give, after sapon., II. Na (R = H, R' = O3). I in vitro inhibited the binding of [3H]PGD2 to PGD2 receptor prepn. from human blood platelet fraction with IC50 of 0.003-8.6 .mu.M. A tablet and granule formulation contg. the title compd. (III.1/2Ca) were described.

IT 106531-16-8P 106531-17-9P 106531-20-4P
 106531-21-5P 106531-22-6P 106531-23-7P
 106531-24-8P 106531-25-9P 106531-26-0P
 106531-27-1P 106531-28-2P 106531-29-3P
 106531-30-4P 106531-31-5P 106531-32-6P
 106531-33-7P 106531-34-8P 106531-35-9P
 106531-36-2P 106531-37-3P 106531-38-4P
 106531-39-5P 106531-40-6P 106531-41-7P
 106531-42-8P 106531-43-9P 106531-47-5P
 106531-48-6P 106531-49-7P 106531-50-8P
 106531-51-9P 106531-52-2P 106531-53-3P
 106531-54-4P 106531-55-5P 106531-56-6P
 106531-62-4P 106531-64-6P 106531-66-8P
 106531-68-0P 106531-70-4P 106531-72-6P
 106531-74-8P 106531-75-9P 106531-76-0P
 106531-77-1P 106531-78-2P 106531-80-6P
 106531-81-7P 106531-82-8P 106531-83-9P
 106531-84-0P 106531-85-1P 106531-86-2P
 106531-87-3P 106531-88-4P 106531-89-5P
 106531-90-6P 106531-91-7P 106531-94-2P
 106531-95-3P 106531-96-4P 106531-97-5P
 106531-98-6P 106531-99-7P 106532-00-3P
 106532-01-4P 106532-02-5P 106532-05-8P
 106532-06-9P 106532-07-0P 106532-08-1P
 106532-09-2P 106532-10-5P 106532-11-6P
 106532-12-7P 106532-13-8P 106532-14-9P
 106532-15-0P 106532-16-1P 106532-17-2P
 106532-18-3P 106532-19-4P 106532-20-7P
 106532-21-8P 106532-22-9P 106532-23-0P
 106532-24-1P 106532-25-2P 106532-26-3P
 106532-27-4P 106532-28-5P 106532-29-6P
 106532-30-9P 106532-31-0P 106532-32-1P
 106532-33-2P 106532-34-3P 106532-35-4P
 106532-36-5P 106532-37-6P 106532-38-7P
 106532-39-8P 106532-40-1P 106532-41-2P
 106532-42-3P 106532-43-4P 106532-44-5P
 106532-45-6P 106532-46-7P 106532-47-8P
 106532-48-9P 106532-49-0P 106532-50-3P
 106532-51-4P 106532-52-5P 106532-54-7P
 106532-56-9P 106532-58-1P 106532-60-5P
 106532-62-7P 106532-63-8P 106532-65-0P
 106532-66-1P 106532-67-2P 106532-68-3P
 106532-69-4P 106532-71-8P 106532-72-9P
 106532-73-0P 106532-74-1P 106532-75-2P
 106532-76-3P 106532-77-4P 106532-80-9P

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS

1997:145245 CAPLUS

EN 126:157408

TI Preparation of N-(arylcycloheptanecarbonyl)amino(carboxyalkenyl)bicycloheptane derivatives or analogs thereof and prostaglandin D2 (PGD2) antagonists containing the same

IN Ohtani, Mitsunaga; Arimura, Akinori; Tsuru, Tatsuo; Kishino, Junji; Honma, Tsunetoshi

PA Shionogi and Co., Ltd., Japan; Ohtani, Mitsunaga; Arimura, Akinori; Tsuru, Tatsuo; Kishino, Junji; Honma, Tsunetoshi

SO PCT Int. Appl., 242 pp.

CODEN: PIXX02

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 970853	A1	19970109	WO 1996-JP1685	19960619
W: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2225250	AA	19970109	CA 1996-2225250	19960619
AU 9661370	A1	19970122	AU 1996-61370	19960619
AU 714312	B2	19991223		
EP 837052	A1	19980422	EP 1996-918841	19960619
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1193315	A	19980916	CN 1996-196326	19960619
BR 9608498	A	19990706	BR 1996-8498	19960619
CZ 258570	B6	19991117	CZ 1997-4013	19960619
JP 3195361	B2	20010806	JP 1997-503724	19960619
JP 2001288160	A2	20011016	JP 2001-73708	19980619
NO 9705994	A	19980223	NO 1997-5994	19971219
US 6172113	B1	20010109	US 1998-973983	19980619
US 6384075	B1	20020507	US 2000-506608	20000218
US 6496190	B1	20021224	US 2000-506606	20000218
PRAI JP 1995-154575	A	19950621		
JP 1997-503724	A3	19960619		
WO 1996-JP1685	V	19960619		
US 1998-973983	A3	19980422		
OS MARPAT 126:157408				
GI For diagram(s), see printed CA Issue.				
AB Compds. of general formula [I; ring Y = Q - Q3; A = alkylene optionally interrupted with phenylene or hetero atoms and optionally contg. oxo and/or unsatd. bonds; B = H, alkyl, aralkyl, acyl; R = CO2R1, CH2OR2, CONR3R4; R1, R2 = H, alkyl; R3, R4 = H, alkyl, OH, alkylsulfonyl; X1 = single bond, phenylene, naphthylene, thiophenediyl, indolediyl, oxazolediyl; X2 = single bond, N=N, N=CH, CH=N, CH=NN, CH=NO, C=NHCN, C=NHCNH, CH=CH, CH(OH), CCl; CCl2, (CH2), C.tplbond.C, NR5, NR5CO, NR5SO2, NR5CONR5, CONR5, SO2NR5, O, S, SO, SO2, CO, oxadiazolediyl, thiadiazolediyl, tetrazolediyl; wherein R5 = H, alkyl; X3 = alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclyl, cycloalkyl, cycloalkenyl, thiazolyldiene, etc.; Z = SO2, CO; m = 0, 1; wherein if the substituents				

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


106532-81-0P 106532-83-2P 106532-85-4P
 106532-87-6P 106532-89-8P 106532-90-1P
 106532-91-2P 106532-92-3P 106532-93-4P
 106532-94-5P 106532-95-6P 106532-96-7P
 106532-97-8P 106532-98-9P 106532-99-0P
 106533-00-6P 106533-04-0P 106533-05-1P
 106533-07-3P 106533-08-4P 106533-09-5P
 106533-13-1P 106533-15-3P 106533-16-4P
 106533-17-5P 106533-18-6P 106533-19-7P
 106533-20-8P 106533-23-3P 106533-24-4P
 106533-25-5P 106533-28-8P 106533-29-9P
 106533-30-2P 106533-31-3P 106533-32-4P
 106533-33-5P 106533-34-6P 106533-35-7P
 106533-36-8P 106533-37-9P 106533-38-0P
 106533-39-1P 106533-40-4P 106533-41-5P
 106533-42-6P 106533-43-7P 106533-44-8P
 106533-45-9P 106533-46-0P 106533-47-1P
 106533-48-2P 106533-49-3P 106533-50-6P
 106533-51-7P 106533-52-8P 106533-53-9P
 106533-54-0P 106533-55-1P 106533-56-2P
 106533-57-3P 106533-58-4P 106533-59-5P
 106533-60-6P 106533-61-7P 106533-62-0P
 106533-63-1P 106533-64-2P 106533-65-3P
 106533-66-4P 106533-67-5P 106533-68-6P
 106533-69-7P 106533-70-0P 106533-71-1P
 106533-72-2P 106533-73-3P 106533-74-4P
 106533-75-5P 106533-76-6P 106533-77-7P
 106533-78-8P 106533-79-9P 106533-80-2P
 106533-81-3P 106533-82-4P 106533-83-5P
 106533-94-8P 106536-04-9P 106536-06-1P
 106536-08-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BTOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of amino(carboxyalkenyl)bicycloheptane derivs. as prostaglandin D2 antagonists for disease therapy)

RN 106531-16-8 CAPLUS


CN 5-Heptenoic acid, 7-[3-[(4-phenylazo)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, [1S-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by R or Z.




L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 186531-17-9 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[4-(phenylazo)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, [1S-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.



RN 186531-20-4 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[4-(phenoxybenzoyl)amino]bicyclo[2.2.1]hept-2-yl]-, [1S-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186531-21-5 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[4-(4-hydroxyphenoxy)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, [1S-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 186531-24-8 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[4-(phenylethynyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186531-25-9 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[4-(phenylethynyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186531-26-0 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[4-([1,1'-biphenyl]-4-ylcarbonyl)amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186531-22-6 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[4-(4-(acetoxyphenoxy)benzoyl)amino]bicyclo[2.2.1]hept-2-yl]-, [1S-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186531-23-7 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[4-(4-methoxyphenoxy)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, [1S-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186531-27-1 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[4-([1,1'-biphenyl]-4-ylcarbonyl)amino]bicyclo[2.2.1]hept-2-yl]-, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186531-28-2 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[4-(phenylazo)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.




L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 186531-29-3 CAPLUS

CN 5-Heptenoic acid, 7-[3-[[4-(phenylazo)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 186531-30-6 CAPLUS

CN 5-Heptenoic acid, 7-[3-[[4-(phenoxybenzoyl)amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 186531-31-7 CAPLUS

CN 5-Heptenoic acid, 7-[3-[[4-(phenoxybenzoyl)amino]bicyclo[2.2.1]hept-2-yl]-, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186531-34-0 CAPLUS

CN 5-Heptenoic acid, 7-[3-[[4-(4-hydroxyphenoxy)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 186531-35-1 CAPLUS

CN 5-Heptenoic acid, 7-[3-[[4-(4-hydroxyphenoxy)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 186531-36-2 CAPLUS

Page 133

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186531-32-8 CAPLUS

CN 5-Heptenoic acid, 7-[3-[[4-(4-(acetyloxy)phenoxy)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 186531-33-9 CAPLUS

CN 5-Heptenoic acid, 7-[3-[[4-(4-(acetyloxy)phenoxy)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

CN 5-Heptenoic acid, 7-[3-[[4-(4-methoxyphenoxy)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 186531-37-3 CAPLUS

CN 5-Heptenoic acid, 7-[3-[[4-(4-methoxyphenoxy)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 186531-38-4 CAPLUS

CN 5-Heptenoic acid, 7-[3-[[4-(4-(acetyloxy)[1,1'-biphenyl]-4-yl)carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186531-39-5 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[[4'-(acetyloxy)[1,1'-biphenyl]-4-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, [1R-[1.alpha., 2.alpha.(Z), 3.beta., 4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186531-40-8 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[[4'-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, [1R-[1.alpha., 2.alpha.(Z), 3.beta., 4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186531-41-9 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[[4'-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, [1R-[1.alpha., 2.alpha.(Z), 3.beta., 4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186531-42-0 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[[4'-methoxy[1,1'-biphenyl]-4-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, [1R-[1.alpha., 2.alpha.(Z), 3.beta., 4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186531-43-1 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[[4'-methoxy[1,1'-biphenyl]-4-yl]carbonyl]amino]bicyclo[2.2.1]hept-2-yl]-, [1R-[1.alpha., 2.alpha.(Z), 3.beta., 4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186531-47-5 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[[4-(acetyloxy)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, [1R-[1.alpha., 2.alpha.(Z), 3.beta., 4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186531-48-6 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[[4-(acetyloxy)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, [1R-[1.alpha., 2.alpha.(Z), 3.beta., 4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186531-49-7 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[[[4-hydroxybenzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, [1R-[1.alpha., 2.alpha.(Z), 3.beta., 4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 186531-50-0 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[(4-hydroxybenzoyl)amino]bicyclo[2.2.1]hept-2-yl]-, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186531-51-1 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[(4-methoxybenzoyl)amino]bicyclo[2.2.1]hept-2-yl]-, methyl ester, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186531-52-2 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[(4-methoxybenzoyl)amino]bicyclo[2.2.1]hept-2-yl]-, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186531-53-3 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[(4-(phenylamino)carbonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186531-54-4 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[(4-(morpholinylcarbonyl)benzoyl)amino]bicyclo[2.2.1]hept-2-yl]-, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186531-55-5 CAPLUS
 CN 5-Heptenoic acid, 7-[3-[(2-phenanthrenylcarbonyl)amino]bicyclo[2.2.1]hept-2-yl]-, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186531-58-8 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[1,1'-biphenyl]-4-ylcarbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186531-62-4 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[1,1'-biphenyl]-4-ylcarbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186531-64-6 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(phenylazo)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as described by E or Z.



L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 186531-66-8 CAPLUS

CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(phenylazo)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

RN 186531-68-0 CAPLUS


CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(phenylazo)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, monosodium salt, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

● Na


RN 186531-70-4 CAPLUS

CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[2-(2-phenylethyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 186531-75-9 CAPLUS

CN 5-Heptenoic acid, 7-[2-[[4-(4-formylbenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

RN 186531-76-0 CAPLUS

CN 5-Heptenoic acid, 7-[2-[[4-[(2,4-dioxo-5-thiazolidinylidene)methyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(Z),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186531-72-6 CAPLUS

CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[2-(2-phenylethyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

RN 186531-74-8 CAPLUS

CN 5-Heptenoic acid, 7-[2-[[4-(4-formylbenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186531-77-1 CAPLUS

CN 5-Heptenoic acid, 7-[2-[[4-[(2,4-dioxo-5-thiazolidinylidene)methyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.(Z),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

RN 186531-78-2 CAPLUS

CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(Z),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186531-80-6 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.(Z),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186531-81-7 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(2-phenylethenyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(E),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186531-84-0 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(2-phenylethenyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.(Z),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186531-85-1 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[(3-benzoylbenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186531-86-2 CAPLUS

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186531-92-8 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(2-phenylethenyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.(E),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186531-93-9 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(2-phenylethenyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(Z),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN 5-Heptenoic acid, 7-[2-[(3-benzoylbenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186531-87-3 CAPLUS
 CN 5-Heptenoic acid, 7-[2-(benzoylamino)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186531-88-4 CAPLUS
 CN 5-Heptenoic acid, 7-[2-(benzoylamino)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186531-89-5 CAPLUS
 CN 5-Heptenoic acid, 7-[2-(benzoylamino)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, monosodium salt, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.
Double bond geometry as shown.

RN 186531-90-8 CAPLUS

CN 5-Heptenoic acid, 7-[2-[(4-benzoylbenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

RN 186531-91-9 CAPLUS

CN 5-Heptenoic acid, 7-[2-[(4-benzoylbenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186531-96-4 CAPLUS

CN 5-Heptenoic acid, 7-[2-[[4-[[[diphenylmethoxy]imino]methyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(E),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 186531-97-5 CAPLUS


CN 5-Heptenoic acid, 7-[2-[[4-[[[diphenylmethoxy]imino]methyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.(E),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 186531-98-6 CAPLUS


Page 138

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186531-94-2 CAPLUS

CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(4-phenoxybenzoyl)amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 186531-95-3 CAPLUS

CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(4-phenoxybenzoyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(4-[(phenylhydrazono)methyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(E),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 186531-99-7 CAPLUS

CN 5-Heptenoic acid, 7-[2-[[4-[(1H-imidazol-1-ylmethyl)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

RN 186532-00-3 CAPLUS

CN 5-Heptenoic acid, 7-[2-[[4-[(1H-imidazol-1-ylmethyl)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-01-4 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(phenylethynyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-02-5 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(phenylethynyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-05-8 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-[(hydroxyimino)methyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(E),3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-06-9 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-[(hydroxyimino)methyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.(E),3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186532-07-0 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-[[[(aminothioxomethyl)hydrazono]methyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(E),3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-08-1 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-[[[(aminothioxomethyl)hydrazono]methyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.(E),3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 186532-09-2 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-[[[(aminocarbonyl)hydrazono]methyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(E),3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-10-5 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-[[[(aminocarbonyl)hydrazono]methyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.(E),3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-11-6 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[[[(phenylamino)carbonyl]hydrazono]methyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(E),3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-12-7 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[[[(phenylamino)carbonyl]hydrazono]methyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.(E),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-13-8 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[[[(phenylamino)thioxomethyl]hydrazono]methyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(E),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-14-9 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[[[(phenylamino)thioxomethyl]hydrazono]methyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.(E),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-15-0 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[(2-phenyl-2H-tetrazol-5-yl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-16-1 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[(2-phenyl-2H-tetrazol-5-yl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-17-2 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-[(2-amino-4-oxo-5(4H)-thiazolylidene)methyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(Z),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-18-3 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-[(2-amino-4-oxo-5(4H)-thiazolylidene)methyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.(Z),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-19-4 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-[(cyanobenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-20-7 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[(4-cyanobenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-21-8 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(1H-tetrazol-5-yl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-22-9 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(1H-tetrazol-5-yl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-23-0 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(1-methyl-1H-tetrazol-5-yl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-24-1 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(1-methyl-1H-tetrazol-5-yl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-25-2 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(2-methyl-2H-tetrazol-5-yl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-26-3 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(2-methyl-2H-tetrazol-5-yl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-27-4 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(2-(4-pyridinyl)ethenyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(Z),3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-28-5 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[2-(4-pyridinyl)ethenyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.(E),3.alpha.(Z),5.alpha.]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-29-6 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[2-(4-pyridinyl)ethenyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(E),3.alpha.(Z),5.alpha.]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-32-1 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[2-(2-thienyl)ethenyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(E),3.alpha.(Z),5.alpha.]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-33-2 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[2-(2-thienyl)ethenyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(E),3.alpha.(Z),5.alpha.]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-30-9 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[2-(4-pyridinyl)ethenyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.(E),3.alpha.(Z),5.alpha.]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-31-0 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[2-(4-pyridinyl)ethenyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(E),3.alpha.(Z),5.alpha.]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-34-3 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[2-(2-thienyl)ethenyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.(E),3.alpha.(Z),5.alpha.]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-35-4 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[2-(2-thienyl)ethenyl]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.(Z),3.alpha.(Z),5.alpha.]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-36-5 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(2-(2-thienyl)ethenyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-37-6 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-(4-(acetyloxy)phenoxy)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186532-40-1 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-(4-hydroxyphenoxy)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186532-41-2 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-(4-methoxyphenoxy)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-38-7 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-(4-(acetyloxy)phenoxy)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186532-39-8 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-(4-hydroxyphenoxy)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 186532-42-3 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-(4-methoxyphenoxy)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-43-4 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[4'-(acetyloxy)[1,1'-biphenyl]-4-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-44-5 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[4'-(acetyloxy)[1,1'-biphenyl]-4-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-45-6 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[4'-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-46-7 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[4'-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-47-8 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[4'-methoxy[1,1'-biphenyl]-4-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-48-9 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[4'-methoxy[1,1'-biphenyl]-4-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-49-0 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[4-(acetyloxy)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-50-3 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[4-(acetyloxy)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186532-51-4 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[4-(hydroxybenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-52-5 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[4-(hydroxybenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-54-7 CAPLUS


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[2-[(4-methoxybenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-56-9 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[(4-methoxybenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-58-1 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(4-oxo-4H-1-benzopyran-2-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-60-5 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(4-oxo-4H-1-benzopyran-2-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-62-7 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[(2-furanylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186532-63-8 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[(2-furanylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-65-0 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(2-thienylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-66-1 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(2-thienylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186532-67-2 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(3-thienylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-68-3 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(3-thienylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-69-4 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(3-thienylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 1]hept-3-yl]-, monosodium salt, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



• Na

RN 186532-71-8 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-(3-thienylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, calcium salt (2:1), [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




• 1/2 Ca

RN 186532-72-9 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-(cyclohexyloxy)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-73-0 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-(cyclohexyloxy)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-74-1 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[5-(phenyl-3-isoxazolyl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-75-2 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[5-(phenyl-3-isoxazolyl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-76-3 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[5-(methyl-3-isoxazolyl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-77-4 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[5-(methyl-3-isoxazolyl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-80-9 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-81-0 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-83-2 CAPLUS
 CN 5-Heptenoic acid, 7-[[1R,2R,3S,5S]-6,6-dimethyl-2-[[4-(phenylthio)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186532-85-4 CAPLUS
 CN 5-Heptenoic acid, 7-[[1R,2R,3S,5S]-6,6-dimethyl-2-[[4-(phenylthio)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 186532-87-6 CAPLUS
 CN 5-Heptenoic acid, 7-[[1R,2R,3S,5S]-6,6-dimethyl-2-[[4-(phenylthio)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, monosodium salt, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



• Na

RN 186532-89-8 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-(chlorobenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-90-1 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-(chlorobenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186532-91-2 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(trifluoromethyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-92-3 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(trifluoromethyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-93-4 CAPLUS


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[[6,6-dimethyl-2-[(4-methylbenzoyl)amino]bicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-94-5 CAPLUS
 CN 5-Heptenoic acid, 7-[[6,6-dimethyl-2-[(4-methylbenzoyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186532-95-6 CAPLUS
 CN 5-Heptenoic acid, 7-[[2-[(1,3-benzodioxol-5-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 186532-98-9 CAPLUS
 CN 5-Heptenoic acid, 7-[[2-[(2-hydroxybenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186532-99-0 CAPLUS
 CN 5-Heptenoic acid, 7-[[2-[(2-methoxybenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186533-00-6 CAPLUS
 CN 5-Heptenoic acid, 7-[[2-[(cyclohexylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186532-96-7 CAPLUS
 CN 5-Heptenoic acid, 7-[[2-[(1,3-benzodioxol-5-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 186532-97-8 CAPLUS
 CN 5-Heptenoic acid, 7-[[2-[[2-(acetoxy)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186533-04-0 CAPLUS
 CN 5-Heptenoic acid, 7-[[2-[(4-bromobenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-05-1 CAPLUS
 CN 5-Heptenoic acid, 7-[[6,6-dimethyl-2-[[4-[[[(phenylamino)carbonyl]amino]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-07-3 CAPLUS
 CN 5-Heptenoic acid, 7-[[6,6-dimethyl-2-[(2-naphthalenylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]-(9CI) (CA INDEX NAME)


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 [3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-08-4 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(1-naphthalenylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186533-09-5 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(2-phenoxybenzoyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 186533-16-4 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[4-(1-methylethoxy)phenoxy]benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-17-5 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[(1H-indol-2-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-18-6 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[(1H-indol-3-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186533-13-1 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[2-oxo-2H-1-benzopyran-3-yl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186533-15-3 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-(4-ethoxyphenoxy)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186533-19-7 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-[2-(4-methoxyphenyl)ethenyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.(E),3.alpha.(Z),5.alpha.]]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-20-0 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-[2-(4-methoxyphenyl)ethenyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.(Z),3.alpha.(Z),5.alpha.]]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186533-23-3 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(phenylsulfonyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- [partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-24-4 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(phenylsulfonyl)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186533-29-9 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(thiazolylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186533-30-2 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-methyl-5-thiazolyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186533-31-3 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[3-methyl-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186533-25-5 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(methylthio)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186533-28-8 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[5-(thiazolylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186533-32-4 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[5-methyl-2-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-33-5 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[2-benzofuranylcarbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-34-6 CAPLUS


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 5-Heptenoic acid, 7-[2-[(1H-benzimidazol-5-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.ha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-35-7 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[5-methyl-1,2,3-thiadiazol-4-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186533-36-8 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(1,2,3-thiadiazol-4-ylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 186533-39-1 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[3,5-dimethyl-4-isothiazolyl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.ha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-40-4 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(4-nitrobenzoyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-41-5 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(3-pyridinylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186533-37-9 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-(dimethylamino)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.ha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186533-38-0 CAPLUS
 CN Benzoic acid, 2-[[[3-(6-carboxy-2-hexenyl)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]amino]carbonyl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186533-42-6 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(2-pyridinylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-43-7 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(4-pyridinylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-44-8 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[4-(dimethylamino)phenoxyl]benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.]]- (9CI) (CA INDEX NAME)


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
ha.}}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-45-9 CAPLUS
CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(2-phenanthrenylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.(Z)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-46-0 CAPLUS
CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(3-phenanthrenylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.(Z)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186533-49-3 CAPLUS
CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(5-methyl-3-thienylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.(Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-50-6 CAPLUS
CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(2-methyl-3-thienylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.(Z)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-51-7 CAPLUS
CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(5-bromo-3-thienylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.(Z)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186533-47-1 CAPLUS
CN 5-Heptenoic acid, 7-[2-[(4-[(4-methoxyphenyl)thio]benzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.(Z)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-48-2 CAPLUS
CN 5-Heptenoic acid, 7-[2-[(benzo[b]thien-2-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.(Z)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186533-52-8 CAPLUS
CN 5-Heptenoic acid, 7-[2-[(4-bromo-3-thienylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.(Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-53-9 CAPLUS
CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(2-methylthio-3-thienylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.(Z)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-54-0 CAPLUS
CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(4-methyl-3-thienylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-55-1 CAPLUS
CN 5-Heptenoic acid, 7-[2-[[4-methoxy-3-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 186533-56-2 CAPLUS
CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[5-(phenylthio)-3-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-60-8 CAPLUS
CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[5-(methylthio)-3-thienyl]carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-61-9 CAPLUS
CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(phenylamino)benzoyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186533-57-3 CAPLUS
CN 5-Heptenoic acid, 7-[2-[[2-bromo-3-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 186533-58-4 CAPLUS
CN 5-Heptenoic acid, 7-[2-[[5-methoxy-3-thienyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 186533-59-5 CAPLUS
CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-(methylthio)-3-

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186533-62-0 CAPLUS
CN 5-Heptenoic acid, 7-[2-[[2-dibenzothiényl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-63-1 CAPLUS
CN 5-Heptenoic acid, 7-[2-[[2-dibenzofuranyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-64-2 CAPLUS
CN 5-Heptenoic acid, 7-[2-[[3-dibenzofuranyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]- (9CI) (CA INDEX NAME)


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
ha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-65-3 CAPLUS
CN 5-Heptenoic acid, 7-[[2-[[2-methoxy-3-dibenzofuranyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.ha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 186533-66-4 CAPLUS
CN 5-Heptenoic acid, 7-[[6,6-dimethyl-2-[(1H-pyrrol-2-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.ha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.ha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 186533-70-0 CAPLUS
CN 5-Heptenoic acid, 7-[[2-[[1-ethyl-1H-pyrrol-3-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.ha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 186533-71-1 CAPLUS
CN 5-Heptenoic acid, 7-[[2-[[1-acetyl-1H-pyrrol-3-yl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.ha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 186533-72-2 CAPLUS

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186533-67-5 CAPLUS
CN 5-Heptenoic acid, 7-[[6,6-dimethyl-2-[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.ha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-68-6 CAPLUS
CN 5-Heptenoic acid, 7-[[6,6-dimethyl-2-[(1H-pyrrol-3-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.ha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-69-7 CAPLUS
CN 5-Heptenoic acid, 7-[[6,6-dimethyl-2-[(1-methyl-1H-pyrrol-3-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.ha.]]- (9CI) (CA INDEX NAME)


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 5-Heptenoic acid, 7-[[1R,2R,3S,5S]-2-[(benzo[b]thien-3-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 186533-73-3 CAPLUS
CN 5-Heptenoic acid, 7-[[6,6-dimethyl-2-[(2-methylbenzo[b]thien-3-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.ha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-74-4 CAPLUS
CN 5-Heptenoic acid, 7-[[6,6-dimethyl-2-[(5-methyl-4-phenyl-3-thienyl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(Z),5.alpha.ha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 186533-75-5 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[[(4,5,6,7-tetrahydrobenzo[b]thien-3-yl)carbonyl]amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-76-6 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[(10,11-dihydro-10-oxodibenzo[b,f]thiepin-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-77-7 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[(10,11-dihydro-10-hydroxydibenzo[b,f]thiepin-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 186533-80-2 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[[4-[(2-methylphenyl)thio]benzoyl]aminobicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186533-81-3 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[(3-furanylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186533-82-4 CAPLUS
 CN 5-Heptenoic acid, 7-[2-(benzoylmethylamino)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]]- (9CI) (CA INDEX NAME)

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 186533-78-8 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[(dibenzo[b,f]thiepin-3-ylcarbonyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 186533-79-9 CAPLUS
 CN 5-Heptenoic acid, 7-[2-[[[(5,5-dioxidodibenzo[b,f]thiepin-3-yl)carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-83-5 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[methyl(3-thienylcarbonyl)amino]bicyclo[3.1.1]hept-3-yl]-, [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 186533-94-8 CAPLUS
 CN 5-Heptenoic acid, 7-[6,6-dimethyl-2-[(4-methylbenzoyl)amino]bicyclo[3.1.1]hept-3-yl]-, calcium salt (2:1), [1R-[1.alpha.,2.beta.,3.alpha.(2),5.alpha.]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



● 1/2 Ca


RN 186536-04-9 CAPLUS
 CN 5-Heptenoic acid, 7-[3-(benzoylamino)bicyclo[2.2.1]hept-2-yl]-,
 [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



RN 186536-06-1 CAPLUS
 CN 5-Heptenoic acid, 7-[3-(benzoylamino)bicyclo[2.2.1]hept-2-yl]-, methyl
 ester, [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 186536-08-3 CAPLUS
 CN 5-Heptenoic acid, 7-[3-(benzoylamino)bicyclo[2.2.1]hept-2-yl]-,

ANSWER 15 OF 17 CAPLUS COPYRIGHT 2003 ACS

RN 1993:559584 CAPLUS
 DN 119:159584
 TI FT-IR spectral study of intramolecular hydrogen bonding in thromboxane A2
 receptor antagonist 5-145 and related compounds. 4
 AU Takasuka, Mamoru; Watanabe, Fumihiko; Yamakawa, Masumi
 CS Shionogi Res. Lab., Shionogi and Co., Ltd., Osaka, 553, Japan
 SO Spectroscopy Letters (1993), 26(6), 1023-37
 CODEN: SPLEBX; ISSN: 0038-7010
 DT Journal
 LA English
 GI




AB An N-methylated compd. (I) of 5-145 (II), its chain analog
 12-(N-methyl(phenylsulfonyl)amino)dodecanoic acid (III), IV and related
 compds. were prepd. in order to study the formation of a new class of
 intramol. hydrogen bond IX (cis-CO2H.cntdot.cntdot.cntdot.O = Y). Their
 FT-IR spectra were measured in dil. CCl4 soln. and subjected to curve
 anal. in order to sep. overlapping absorption bands. For compds. I, III
 and IV, the intramol. hydrogen bonds of the IX type involving 14-, 17- and
 14-membered rings were found between a carboxyl group, which takes a
 cis-structure, and an oxygen atom of a sulfonyl or benzoylamino group,
 resp. The C=O stretching vibration bands of these carboxyl groups shifted
 to lower wavenumbers (ca. 19 cm-1). The direction of these shifts was
 contrary to that found for .alpha.-keto and .alpha.-alkoxycarboxylic acids
 in which carboxyl groups take a trans-structure due to the formation of
 intramol. hydrogen bonds.

IT 115586-60-2
 RL: PRP (Properties)
 (hydrogen bonding in, intramol., FT-IR study of)


RN 115586-60-2 CAPLUS
 CN 5-Heptenoic acid, 7-[3-(benzoylamino)bicyclo[2.2.1]hept-2-yl]-,
 [1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 [1R-[1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



ANSWER 16 OF 17 CAPLUS COPYRIGHT 2003 ACS

RN 1988:492336 CAPLUS
 DN 109:92336
 TI Synthesis and in vitro activity of various derivatives of a novel
 thromboxane receptor antagonist, (1R)-5-(2)-7-[3-
 endo(phenylsulfonyl)amino]bicyclo[2.2.1]hept-2-enoic acid
 AU Narisada, Masayuki; Ohtani, Mitsuaki; Watanabe, Fumihiko; Uchida,
 Kiyohisa; Arita, Hitoshi; Otsuchi, Masami; Hanasaki, Koji; Kakushi,
 Hisato; Otani, Koichi; Hara, Seiji
 CS Shionogi Res. Lab., Shionogi and Co., Ltd., Osaka, 553, Japan
 SO Journal of Medicinal Chemistry (1988), 31(9), 1847-54
 CODEN: JMCHAR; ISSN: 0022-2623
 DT Journal
 LA English
 OS CASREACT 109:92336
 GI




AB The sulfonamides I (R = Ph, substituted Ph, phenylalkyl, Me, hexyl,
 naphthyl) (20 compds) were prepd. by sulfonation of Me
 (1R)-5-(2)-7-[3-endo-aminobicyclo[2.2.1]hept-2-enoic acid
 followed by sapon. Inhibitory concns. (IC50) of the Na salts of I for platelet
 aggregation were measured. IC50 values of some deriva. for contraction of
 the rat aorta were also measured. The IC50 values for platelet
 aggregation increased from 2.9 to 26 nM in the order I (R = Ph, CH2CH2Ph,
 (CH2)3Ph, CH2Ph). I (R = Me) exhibited a higher IC50 value than I (R =
 hexyl). Substitution on I (R = Ph) by a p-Me, p-F-, or p-Cl retained or
 slightly reduced its IC50 value, while a p-n-pentyl or p-CO2H augmented it
 significantly. I (R = Ph) suppressed (15S)-15-hydroxy-11,9-
 (epoxymethano)prosta-5(2),13(E)-dienic acid induced aggregation of human
 platelets with an IC50 value of 7.7 nM. Synthesis of thromboxane A2
 (TxA2) in human platelets stimulated by thrombin was not inhibited by I (R
 = Ph). Itoreq.10 .mu.M. Thus, I (R = Ph) was concluded to be a potent
 TxA2 receptor antagonist.

IT 115206-10-3P 115586-60-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and blood platelet aggregation inhibiting activity of)

RN 115206-18-3 CAPLUS
 CN 5-Heptenoic acid, 7-[3-(benzoylamino)bicyclo[2.2.1]hept-2-yl]-, monosodium
 salt, [1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.


L8 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



• Na

RN 115586-60-2 CAPLUS

CN 5-Heptenoic acid, 7-[3-(benzoylamino)bicyclo[2.2.1]hept-2-yl]-, [1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.

IT 115206-17-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. and ester hydrolysis of)

RN 115206-17-2 CAPLUS

CN 5-Heptenoic acid, 7-[3-(benzoylamino)bicyclo[2.2.1]hept-2-yl]-, methyl ester, [1.alpha.,2.alpha.(Z),3.beta.,4.alpha.]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

ANSWER 17 OF 17 CAPLUS COPYRIGHT 2003 ACS

AN 1986:572164 CAPLUS

DN 105:172164

TI 13-Aza-14-oxothromboxane A2 analogs

IN Miyake, Haniroku; Okegawa, Tadao; Kawasaki, Akiyoshi

PA Ono Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 58 pp.


CODEN: JOKXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 61000049	A2	19860106	JP 1984-119000	19840612
	JP 01042938	B4	19890918		
	ZA 8504237	A	19860326	ZA 1985-4237	19850604
	CA 1261826	A1	19890926	CA 1985-483112	19850604
	NO 8502319	A	19851213	NO 1985-2319	19850610
	FI 8502319	A	19851213	FI 1985-2319	19850611
	DK 8502600	A	19851213	DK 1985-2600	19850611
	HU 37914	A2	19860328	HU 1985-2294	19850611
	HU 196740	B	19890130		
	ES 544054	A1	19870501	ES 1985-544054	19850611
	US 4792550	A	19881220	US 1985-743548	19850611
	AU 8543495	A1	19851219	AU 1985-43495	19850612
	AU 575653	B2	19880804		
	EP 171146	A1	19860212	EP 1985-304148	19850612
	EP 171146	B1	19880928		
PRAI	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 37535	E	19881015	AT 1985-304148	19850612
	ES 552192	A1	19870416	ES 1986-552192	19860219
	JP 01151545	A2	19890614	JP 1988-288776	19881117
	JP 03053295	B4	19910814		
GI	JP 1984-119000		19840612		
	EP 1985-304148		19850612		



AB Title compds. I (R1 = H, alkyl; R2 = bond, (un)substituted alkylene, alkenylene; R3 = (un)substituted Ph, phenoxyl, phenylthio, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkoxy, cycloalkylthio, naphthyl, indanyl, amino; R4 = H, Me) and their salts, useful as thromboxane A2 antagonists (platelet aggregation inhibitor data in human given), were prepd. Thus, N-acylation of Me 6-[(1S,2S,3S,5R)-3-aminopinan-10-yl]hex-5(2)-enoate with a mixed anhydride, prepd. from 2S-hydroxy-3-phenylpropionic acid and

L8 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


pivaloyl chloride, gave Me 9.alpha.,11.alpha.-dimethylmethano-13-aza-14-oxo-15.alpha.-hydroxy-16-phenyl-17,18,19,20-tetranor-11a-carbathrombox-5(2)-enoate.

IT 103080-65-5P 103080-70-2P 104580-73-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. of, as thromboxane A2 antagonist)


RN 103080-65-5 CAPLUS

CN 5-Heptenoic acid, 7-[3-[[[3-butylcyclopentyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-2-yl]-, [1S-[1.alpha.,2.beta.(Z),3.alpha.,5.alpha.]- (9CI) (CA INDEX NAME)




RN 103080-70-2 CAPLUS

CN 5-Heptenoic acid, 7-[3-[[[3-butylcyclopentyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-2-yl]-, [1S-[1.alpha.,2.beta.(Z),3.alpha.,5.alpha.]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 104580-73-6 CAPLUS

CN 5-Heptenoic acid, 7-[3-[[[3-butylcyclopentyl]carbonyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-2-yl]-, [1S-[1.alpha.,2.beta.(Z),3.alpha.,5.alpha.]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

09/936,161

=> d bib abs 1-4 116

09/936,161

L16 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 2001:904102 CAPLUS

DN 136:37614

TI Preparation of chiral heterocyclylcarbonylaminobicycloheptanhydrocarbons
rboxylic acids in remedy composition antagonistic to both PGD2 and TXA2
receptors

IN Tanimoto, Norihiko; Arimura, Akinori

PA Shionogi & Co., Ltd., Japan

SO PCT Int. Appl., 278 pp.

CODEN: PIXXD2

DT Patent

LA Japanese



FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001094309	A1	20011213	WO 2001-JP4430	20010528
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BG, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI JP 2000-166305 A 20000602

OS MARPAT 136:37614

GI



AB Title compds. [I; A = alkylene optionally having an unsatd. bond; R = COR1, CH2OCH3, CH2OH; R1 = OH, OCH3, NH2, NHSO2CH3; X1, X3 independently = optionally substituted aryl, optionally substituted heteroaryl; X2 = single bond, CH2, S, SO2, CH2O, OCH2, CH2S, SCH2; Y = bicycloheptane] and

L16 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)

pharmaceutically acceptable salts or solvates, having antagonistic effect on both thromboxane A2 and prostaglandin D2 receptors, are prepd. Thus, the title compd. II was prepd. and biol. tested for TXA2 receptor antagonistic activity with IC50(.mu.M) = 0.011 and PGD2 receptor antagonistic activity with IC50(.mu.M) = 0.079.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS

AN 2000:645983 CAPLUS

DN 133:222579

TI Preparation of [2.2.1] and [3.1.1]bicycloheptane antagonistic to both of PGD2/TXA2 receptors

IN Honma, Tsunetoshi; Hiramatsu, Yoshiharu; Arimura, Akinori

PA Shionogi and Co., Ltd., Japan

SO PCT Int. Appl., 251 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000053573	A1	20000914	WO 2000-JP1223	20000302
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1176139	A1	20020130	EP 2000-906622	20000302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRAI JP 1999-62721 A 19990310

WO 2000-JP1223 W 20000302

OS MARPAT 133:222579

GI



AB Medicinal compns. contg. the title compds. [I; ring Y = Q, Q1, Q2; R1 = CH2CH:CH(CH2)3CO2R2, CH:CH(CH2)3CO2R2; wherein R2 = H, alkyl; m = 0, 1; p = 0, 1; when p = 0, X1 and X3 are not linked to each other through X4; X1, X3 = (un)substituted aryl or heteroaryl; X2 = CH2, CH2CH2, CO, O, S, SO, SO2, NH, NHMe, C(NOMe), N:N, CH:CH, CONH, NHCO, CH2NH, NHCH2, CH2O, OCH2, CH2S, SCH2, CH2SO2, SO2CH2, SO2NH, NHSO2; X4 = CH2, CH2CH2, CO, SO, SO2, CONH, NHCO, CH2NH, NHCH2, CH2O, OCH2, CH2S, SCH2, CH2SO2, SO2CH2, SO2NH, NHSO2], prodrugs or pharmaceutically acceptable salts thereof, or hydrate

L16 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 2000:368150 CAPLUS

DN 133:12765

TI Preventives and/or remedies for central nervous system diseases containing compounds having TXA2 receptor antagonism and/or TXA2 synthase inhibitory effect

IN Yagami, Tatsuro; Honma, Tsunetoshi; Katsura, Goro

PA Shionogi & Co., Ltd., Japan

SO PCT Int. Appl., 171 pp.

CODEN: P1XXD2

UT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000030683	A1	20000602	WO 1999-JP6317	19991112
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI JP 1998-329852 A 19981119

OS MARPAT 133:12765

AB Compds. having TXA2 antagonism and/or a TXA2 synthase inhibitory effect, prodrugs thereof, pharmaceutically acceptable salts of the same or hydrates of the same, which show effects of inhibiting nerve cell denaturation caused by amyloid .beta. protein and nerve cell death caused by axonotmesis, are useful as preventives and/or remedies for central nervous system diseases, preventives and/or remedies for nerve degeneration diseases, nerve cell denaturation inhibitors, amyloid .beta. protein-induced nerve cell denaturation inhibitors, nerve cell death inhibitors, axonotmesis-induced nerve cell death inhibitors and, in particular, preventives and/or remedies for dementia of Alzheimer type.

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1997:145245 CAPLUS

DN 126:157408

TI Preparation of N-(arylcarbonyl or heterocyclylcarbonyl)amino(carboxyalkenyl)bicycloheptane derivatives or analogs thereof and prostaglandin D2 (PGD2) antagonists containing the same

IN Ohtani, Mitsunori; Arimura, Akinori; Tsuru, Tatsuo; Kishino, Junji; Honma, Tsunetoshi

PA Shionogi and Co., Ltd., Japan; Ohtani, Mitsunori; Arimura, Akinori; Tsuru, Tatsuo; Kishino, Junji; Honma, Tsunetoshi

SO PCT Int. Appl., 242 pp.

CODEN: P1XXD2

UT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9700853	A1	19970109	WO 1996-JP1685	19960619
W:	AL, AU, BB, BG, BR, CA, CN, CZ, DE, EE, GE, GR, HU, IL, IS, JP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2225250	AA	19970109	CA 1996-2225250	19960619
AU 9661370	A1	19970122	AU 1996-61370	19960619
AU 714312	B2	19991223		
EP 837052	A1	19980422	EP 1996-918841	19960619
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI			
CN 1193315	A	19980916	CN 1996-196326	19960619
BR 9608498	A	19990706	BR 1996-8498	19960619
CZ 285970	B6	19991117	CZ 1997-4013	19960619
JP 3195361	B2	20010806	JP 1997-503724	19960619
JP 2001288160	A2	20011016	JP 2001-73708	19960619
NO 970594	A	19980223	NO 1997-5994	19971219
US 6172113	B1	20010109	US 1998-973983	19980422
US 6384075	B1	20020507	US 2000-506608	20000218
US 6498190	B1	20021224	US 2000-506606	20000218
PRAI JP 1995-154575	A	19950621		
JP 1997-503724	A3	19960619		
WO 1996-JP1685	V	19960619		
US 1998-973983	A3	19980422		

OS MARPAT 126:157408

GI For diagram(s), see printed CA Issue.

AB Compds. of general formula [I; ring Y = Q - Q3; A = alkylene optionally interrupted with phenylene or hetero atoms and optionally contg. oxo and/or unsatd. bonds; B = H, alkyl, aralkyl, acyl; R = CO2R1, CH2OR2, CONR3R4; R1, R2 = H, alkyl; R3, R4 = H, alkyl, OH, alkylsulfonyl; X1 = single bond, phenylene, naphthylene, thiophenediyl, indolediyl, oxazolediyl; X2 = single bond, N=N, N=CH, CH=N, CH=NO, C=NNHCSNH, C=NNHCONH, CH=CH, CH(OH), CCl, (CH2)n, C.tplbond.C, NR5, NR5CO, NR5SO2, NR5CONR5, CONR5, SO2NR5, O, S, SO2, CO, oxadiazolediyl, thiadiazolediyl, tetrazolediyl; wherein R5 = H, alkyl; X3 = alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclyl, cycloalkyl, cycloalkenyl, thiazolyldiene, etc.; Z = SO2, CO; m = 0, 1; wherein if the substituents

L16 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS (Continued)

are in the form of rings, they may be optionally substituted) or salts thereof or hydrates thereof are prepd. These compds. are useful as a PGD2 antagonists and thus usable in, for example, a remedy for systemic mastocytosis or systemic mast cell activation disorders, a drug for bronchoconstriction, an antiasthmatic, a drug for allergic rhinitis agent, a drug for allergic conjunctivitis, a drug for urticaria, a remedy for ischemia reperfusion disorders or an antiinflammatory agent. They are particularly useful in the treatment of nasal occlusion. Thus, a bicyclo[2.2.1]heptane deriv. (III; R = Me, R7 = H) was condensed with 2-chlorosulfonyldibenzofuran in the presence of Et3N in CH2Cl2 to give, after sapon., II .Na (R = H, R7 = Q3). I in vitro inhibited the binding of [3H]PGD2 to PGD2 receptor prepn. from human blood platelet fraction with IC50 of 0.003-8.6 .mu.M. A tablet and granule formulation contg. the title compd. (III.1/2Ca) were described.